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ABSTRACT 
Mycobacterium tuberculosis (Mtb) is the leading cause of death from an infectious disease. 
The success of the pathogen lies in its ability to subvert hostile intracellular macrophage 
environment. We performed genome-wide transcriptional deep sequencing on total RNA in 
murine bone marrow-derived macrophages (BMDM) infected with hypervirulent Beijing strain 
(HN878) in an extensive time kinetic manner using single molecule sequencer and cap analysis 
gene expression (CAGE) technique. CAGE analysis revealed nearly 36000 unique RNA 
transcripts with approximately 16000 are not unannotated to a specific gene. This thesis addressed 
global changes in RNA expression levels in macrophages infected with Mtb in a time kinetic 
manner to pinpoint novel host protection and immune evasion genes and elucidate the role of these 
genes in vitro macrophage assays and in vivo knockout mouse studies.  
The data in this thesis showed that basic leucine zipper transcription factor 2 (Batf2) was 
an important factor that regulates inflammatory responses in Mtb infection. Deletion of Batf2 led 
to the survival of mice with reduced lung inflammation and histopathology due to reduced 
recruitment of inflammatory macrophages. We also showed that Batf2 was highly expressed in 
peripheral blood from adolescents who progressed from infection to tuberculosis disease and a 
predictive human biomarker for tuberculosis disease. In contrast to Batf2, we showed that Protein 
Kinase C-delta (PKC-δ) deficient mice are highly susceptible to tuberculosis and human lung 
proteomics dataset revealed that PKC-δ was highly upregulated in the necrotic and cavitory 
regions of human granulomas in multi-drug resistant subjects. PKC-δ deficient mice had a 
significant reduction in alveolar macrophages and dendritic cells, reduced accumulation of lipid 
bodies and serum fatty acids. In vitro experiments showed that PKCδ was required for optimal 
killing effector functions which were independent of phagosome maturation and autophagy in 
primary murine macrophages. Our studies suggested that these novel genes play a role in the 
immune response to Mtb and should be studied more thoroughly to evaluate their potential in 
possible TB interventions. 
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CHAPTER I 
LITERATURE REVIEW 
1. HISTORY of TUBERCULOSIS 
Tuberculosis has been haunting the humankind for centuries. The etiologic agent 
mycobacteria were hypothesized to be existing since the Jurassic geological period nearly 150 000 
years [1]. The initial analysis of mycobacterial DNA in human remains using various genotyping 
methods introduced the hypothesis that Mycobacterium tuberculosis (Mtb) emerged through 
zoonotic transmission of ancient Mycobacterium bovis during domestication of cows [2]. With the 
advent of whole genome sequencing and comparative genomic analyses, it was revealed that 
M.bovis is actually nested within a tree of human adapted lineage of Mycobacterium africanum 
which is restricted to Western Africa. In a recent analysis, the deepest origins of Mtb are traced 
back to ancestral species that are predominantly environmental and human pathogenesis arose by 
the occurrence of several transitions [3].  
The earliest evidence of Mtb has been found in the bones of extinct bison from Wyoming, 
USA dating back to 17000 years ago by PCR sequencing and detection of mycobacterial lipids [4, 
5]. The earliest human tuberculosis evidence was found in an infant and woman buried together in 
an Eastern Mediterranean village with evidence of agriculture and animal domestication dating 
back to 9000 years ago [6]. In ancient Greece, Hippocrates (460-376 BC) named the disease as 
“phthisis” which translates to wasting. He described phthisis as mostly fatal, with constant sweats 
but not diffused all around the body, attacked mainly young adults, occurred mostly in summer 
and autumn rather than acute respiratory infections of winter seasons, and recommended a special 
diet based on wine, bread and milk [7].  
“White plague” surged to nearly 1000 deaths per 100 000 population across Europe and 
reported responsible for up to 25% of deaths in the 19th century. It was deemed as poor people’s 
ailment; however, tuberculosis affected all layers of society while poverty was definitely exerting 
substantial effects [8]. A German physician Hermann Brehmer changed the course of tuberculosis 
treatment by housing the victims of tuberculosis in healthy havens, sanatoriums. He initially 
believed the disproportionate ratio of heart and lung sizes of his patients is the main reason and 
the constant low air pressure at high altitude would lead to enlargement of heart sizes. In 1854, the 
first facility for treatment of tuberculosis was constructed in Görbersdorf, Silesia on Sudeten 
Mountains with the help of his friend Alexander von Humboldt and it was called Heilenstalt 
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translated as a healing place. Such facilities were prevalent for the treatment of the disease over 
the next century and called sanitarium which comes from Latin sanare to heal [9].  
French physician Jean Antoine Villemin proved the first time that tuberculosis was contagious 
by transferring tuberculous material from bovine and humans to rabbits and established an 
etiological link [10]. The prodigious event in tuberculosis history was the discovery of the cause 
of tuberculosis by the German physician Robert Koch on 1882 [11]. Robert Koch and Paul Ehrlich 
modified alcohol-methylene blue staining and the technique was finalized by Franz Ziehl and 
Friedrich Neelsen [12]. Using new staining method, Koch described that the culprit bacteria are 
rod-shaped looking similar to leprosy bacilli and present in a group within the lesions. Besides 
that, Koch was also successful to isolate Mtb and culture them from infected guinea pigs, bovine, 
and humans. Koch proved his postulates that; 
i) The infectious agent of tuberculosis was observed in tuberculous lesions but not in 
other lesions or in healthy tissues. 
ii) Mtb was isolated from a diseased organism and cultured in vitro outside the infected 
organism. 
iii) After growing in vitro, the cultured Mtb caused disease when reintroduced into a 
healthy animal, causing tuberculous lesions. 
iv) The infectious agent was then reisolated from the inoculated, diseased host and 
identified as being identical to the original agent. 
Koch also observed that non-inoculated guinea pigs that were housed in the same room with 
infected guinea pigs showed signs of tuberculosis which proved the airborne route of transmission 
for Mtb. A few years after Koch identified Mtb, he reported on an inexplicable substance that can 
alleviate tuberculosis. He revealed that the substance was purified from Mtb supernatant grown in 
vitro that is currently known as tuberculin. Despite his unsuccessful attempts to prove tuberculin 
ameliorates the disease, it became a key component of tuberculosis diagnostics that is still used 
widespread nowadays.  Robert Koch was granted the Nobel Prize in Physiology or Medicine in 
1905 for his investigations and discoveries in tuberculosis field. 
 Although Koch was unsuccessful with his hypothesis about tuberculin, French physician 
Charles Mantoux described the use of cannulated syringe and needle to inject tuberculin 
intracutaneously which would lead to a reaction in individuals that are latently infected, not 
manifesting tuberculosis symptoms. Mantoux test, aka tuberculin skin test, was first described in 
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1908 led to an understanding of much of physiopathology of tuberculosis infection and is still 
widely used with well standardized purified protein derivative injections.  
Perhaps French physician Albert Calmette and veterinarian Camille Guérin had more 
substantial effects among early 20th-century tuberculosis researchers in terms of public health. 
They used the organism known as Mycobacterium bovis (M.bovis) which was isolated from 
tuberculous cow to develop a vaccine. However; they were stymied by the presence of clumps in 
their liquid culture and they added ox bile to prevent clumping which resulted in a consequential 
decrease in virulence in M.bovis infected guinea pigs [13]. With their laborious effort, the bacteria 
were subcultured more than 200 times between 1908 and 1921. The first human Bacillus Calmette 
Guérin (BCG) vaccine recipient was a 3-day old infant whose mother died of tuberculosis just 
after birth and grandmother had smear-positive tuberculosis. After three doses of oral 
administration of BCG vaccine, the infant did not show any signs of tuberculosis at 6 months in 
spite of constant exposure from the grandmother. Over the following 7 years, 100 000 children 
were vaccinated in Europe and the vaccine was used United States, Canada, and all the countries 
in South America [14].  
As the housing and nutrition standards started to improve in early 20th century, the death toll 
started to drop before the onset of treatment with antituberculosis drugs. Edward Livingston 
Trudeau was one of the noteworthy scientists in the history of the fight against tuberculosis in the 
late 19th and early 20th century.  After contracting the disease, he established Saranac Laboratory 
for Study of Tuberculosis later renamed Trudeau Institute as the first research organization to study 
tuberculosis in the United States. He performed many experiments with tubercular rabbits to study 
the efficacy of different treatment options. He pointed out the significance of chemotherapy for 
tuberculosis in an article published after his death from tuberculosis. “My faith in the possibilities 
of chemotherapy for tuberculosis is based simply on what Ehrlich has demonstrated as possible in 
syphilis --namely, that a chemical compound could be discovered which killed the germ without 
injuring the cell… Such an agent, when properly used, would prove of great value in the treatment 
of this disease.”  [15]. As a side note, Paul Ehrlich whom Trudeau mentioned in his excerpt, is 
1908 Nobel Prize laureate in Physiology and Medicine for his contributions in the field of 
immunity and his laboratory discovered first antibacterial, Salvarsan for the treatment of syphilis 
in 1909. Salvarsan was the first sensational victory of a systemic chemotherapy against a 
microorganism. 
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Table 1.1: Historical landmarks in tuberculosis research and treatment 
The governing theory during sanatorium era was that if the rest was beneficial for tuberculosis 
patients, rest of tuberculous lungs might be beneficial, too. Thus, novel therapeutic interventions 
like artificial pneumothorax aiming pulmonary collapse were introduced. The physicians forced 
nitrogen or air into the pleural cavity resulting in collapsing of the lung, cavity closure and sputum 
conversion to negative. Although pneumothorax method was not rigorously checked for efficacy, 
the first study from Denmark illustrated that 191 sputum-positive patients that received artificial 
pneumothorax intervention between 1925 and 1931 resulted in 107 successful cases [16]. The 
other collapse therapies which were used for treatment of cavitary pulmonary tuberculosis were 
artificial pneumoperitoneum (increasing intraperitoneal pressure by administering air and 
elevating diaphragm), thoracoplasty (surgical removal of several rib bones), plombage (creating 
Year Historical Step 
1854 Hermann Brehmer established the first anti-tuberculosis sanatorium in 
Gӧrbersdorf, Poland. 
1869 Jean Antoine Villemin proved tuberculosis is contagious by injecting 
tuberculous matter from human cadavers to rabbits. 
1882 Robert Koch reported that the disease was caused by an infectious agent. 
1894 Edward Livingston Trudeau established the first center to study tuberculosis 
in Saranac Lake, New York. 
1906 Albert Calmette and Camille Guerin developed attenuated Mycobacterium 
bovis strain as BCG vaccine. 
1944 Albert Schatz and Selman Waksman discovered streptomycin 
1946 Jorgen Lehmann discovered para-aminosalicylic acid (PAS) 
1951 Three independent groups in Squibb Institute New Jersey, Hoffmann-La 
Roche and Bayer reported anti-tuberculosis drug, isoniazid. 
1952 Sir John Crofton revolutionizes TB chemotherapy by introducing 
streptomycin + para-aminosalicylic acid+ isoniazid combination therapy 
1956 Commencement of Madras study 
1961 Ethambutol was discovered 
1966 Rifampicin was introduced to TB drug pipeline 
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cavity underneath the rib cage and filling with inert material like olive oil or Lucite ball), phrenic 
nerve crush (cutting off the nerve to diaphragm that is paralyzed, remains in relaxed and elevated 
state) and pulmonary resection which is presently still effective for drug-resistant cases.     
With the onset of antituberculosis chemotherapy, lung collapse therapies and sanatoriums 
were starting to become expendable. Most of the sanatoriums were closed by 1960s; furthermore, 
patients receiving treatment promptly became non-infectious showing efficacy of ambulatory 
treatment. The Madras study which was designed to compare the treatment of patients with 12 
months at home or in sanatorium showed no difference between hospital care and home treatment 
in either treatment outcomes or infection of household contacts [17]. 
American chest physician Corwin Hinshaw and his collaborator veterinarian William 
Feldman are the pioneers of the chemotherapy against this global scourge. They developed a 
guinea pig model of tuberculosis that enabled them to check the efficacy of candidate compounds 
meticulously. The first candidate was developed in 1940, dapsone-derived compound promine, 
was successful in guinea pigs, had promising results in first human trials; however, the drug did 
not convince National Tuberculosis Association to be introduced as a first anti-TB drug. 
Nonetheless, the drug was shown to favorably cure leprosy and became the treatment of choice 
[18]. The history of tuberculosis treatment was changed by the discovery of streptomycin, first 
bactericidal chemical effective against Mycobacterium tuberculosis to be later used in humans. 
Russian biochemist Selman Waksman and his Ph.D. student American microbiologist Albert 
Schatz discovered streptomycin in Rutgers University, New Jersey [19].  Waksman later sent a 
limited amount of streptomycin to Hinshaw and Fendman to check in Mtb infected guinea pigs. 
Their first result conclusively reported that streptomycin would arrest and at times eradicate 
tuberculous lesions in guinea pigs [20]. British Medical Research Council reported the first 
controlled trial of streptomycin on TB patients by randomly assigning them streptomycin plus bed-
rest or bed-rest only groups. After 6 months of treatment; 51 of 55 (93%) streptomycin-treated 
patients versus 38 of 52 (73%) control group patients survived [21]. After 5 years, another Medical 
Research Council trial did not find any significant differences between streptomycin-treated and 
control arms by virtue of the acquired streptomycin resistance of the bacilli [22]. 
Swedish physician and chemist Jörgen Lehmann was a skilled scientist to work on metabolism 
on tubercle bacillus. With the hint of previous work done on salicylates, he discovered that 
salicylates increased the oxygen consumption of pathogenic strains in culture but not non-
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pathogenic BCG strain [23]. In an accompanying article, he tried nearly 50 derivatives of 
salicylates to find competitive inhibitors with the idea that these inhibitors might have 
bacteriostatic effects. He discovered para-aminosalicylic as a potent anti mycobacterial agent in 
culture, in rats and in two TB patients [24]. Although PAS was discovered earlier than 
streptomycin, the acceptance by Swedish authorities slowed its introduction of treatment for 
tuberculosis. 
Three independent groups, scientists from Bayer Chemical in Germany, Hoffman-La Roche, 
and Squibb in the United States, discovered efficacious, safe and inexpensive wonder drug 
isoniazid extraordinarily at the same time in 1951. Time-consuming and tortuous patent war was 
luckily avoided since it was noticed that two Czech Ph.D. students synthesized the drug without 
knowing its profound potential in TB treatment 40 years earlier [25]. After the introduction of 
isoniazid into TB drug pipeline, many trials were conducted to optimize the triple therapy which 
consisted of oral isoniazid with PAS for 18 to 24 months and intramuscular streptomycin injection 
for the first 6 months. This regimen was called “Edinburgh Method” which was pioneered by Sir 
John Crofton and his team at Edinburgh University and it formed the basis of today’s TB drug 
regimens.  
The manifestation of side effects, the emergence of drug resistance and the increasing burden 
of tuberculosis incidents motivated TB drug development. In 1961, a synthetic compound 
ethambutol was found to be comparable with isoniazid when given orally and comparable with 
streptomycin when given parenterally in mice. It was effective on isoniazid and streptomycin 
resistant mycobacteria [26]. Initially, ethambutol was administered in retreatment cases and was 
found to be well-tolerated compared to PAS. Clinical trials showed that low doses of ethambutol 
were as effective as standard PAS dosage in sputum conversion which provided less bulky, better 
tolerated and less expensive alternative to physicians [27].   
Rifamycins were first synthesized naturally from bacterium Amycolatopsis rifamycinica 
which was isolated from soil samples in southern France in 1957 [28]. Rifampicin is the synthetic 
orally active form of rifamycin SV. Rifampicin was first introduced in clinical trials in 1966 and 
in the next decade, it became the essential component of TB regimens. Treatment with rifampicin 
plus isoniazid supplemented by ethambutol for first two months decreased therapy duration to 9 
months with decreased relapse rates in 1976 clinical trial completed in Britain [ 29].  
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In late 1940s nicotinic acid was found to markedly suppress the spread of tuberculosis on 
experimentally infected Swiss mice [30]. Later pyrazinamide (nicotinic acid analog) was 
discovered to be bacteriostatic only in acidic pH. Initial clinical trials showed that pyrazinamide 
was equally as effective as PAS in combination treatments with isoniazid; however, hepatotoxicity 
was a significant side effect of pyrazinamide treatment. Hence, it was not recommended for use in 
the initial phase of TB treatment [31]. Singapore Tuberculosis Service and British Medical 
Research Council trial result announced in 1979 showed that two months intensive phase of 
streptomycin, isoniazid, rifampicin, and pyrazinamide followed by 4-month isoniazid and 
rifampicin continuation phase was very effective in TB treatment [32]. Additional 
antimycobacterials; cycloserine [33], ethionamide [34], kanamycin [35], capreomycin [36] 
developed during late 1950s played important role in drug-resistant cases.  
2. TUBERCULOSIS: CURRENT SITUATION and INSIGHTS 
Despite the discovery of first anti-tuberculosis drugs more than 70 years ago, tuberculosis still 
accounts for 1.5 million deaths each year. In 2014, there were estimated 9.6 million new cases of 
active tuberculosis worldwide (5.4 million men, 3.2 million women, and 1 million children). 
Among 9.6 million people fallen sick with TB, estimated 1.2 million people were co-infected with 
HIV. TB killed 1.5 million people including 390 000 deaths among HIV-infected patients showing 
a slight decrease from peak numbers in the mid-2000s [37]. It is predicted that there were 480 000 
multi-drug resistant tuberculosis cases defined as resistance to at least rifampicin and isoniazid, 
the two most efficacious anti-TB drugs. More than 40% of these cases were reported in India, 
China, Russia, Ukraine, and the Philippines. A total of 105 countries has reported extensively drug-
resistant cases defined as multidrug resistance plus resistance to at least one fluoroquinolone and 
any of three second-line injectables, kanamycin, amikacin and capreomycin. Nearly 9.7% of multi-
drug resistance cases were extensive drug-resistant with Belarus (29%) and Lithuania (25%) being 
highest. Sub-Saharan African countries have the highest estimated TB incidence rates, driven 
mainly by HIV epidemic. The absolute number of TB cases is highest in Asian countries, China, 
India, and Indonesia having the greatest epidemiological burden of the disease globally. In Western 
highly developed countries, the considerable amount of cases occur in foreign-born residents and 
immigrants from TB endemic countries [38].  
Active pulmonary tuberculosis patients are the source of Mtb. Nearly 90% of individuals 
infected with Mtb, they contain the pathogen as asymptomatic latent infection and they have 10% 
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chance of developing active disease in their lifetime. Some individuals may eliminate acute Mtb 
infection according to recent studies [39]. There are 2 billion people latently infected with Mtb on 
the estimate and are at risk of TB reactivation. Interestingly; latently infected individuals much 
lower risk of progressive tuberculosis on repeated exposure than uninfected individuals [40]. In 
contrast, individuals treated successfully for TB are associated with increased risk of developing 
TB from reinfection than new cases of TB [41].   
3. TUBERCULOSIS IMMUNOPATHOLOGY 
The immunopathological hallmark of Mtb infection is the granuloma. To simply define 
granuloma, it is organized collection of mononuclear phagocytes, neutrophils, and lymphocytes 
(Figure 1.1). Granuloma formation initiates when inhaled bacilli interact and are phagocytosed by 
alveolar macrophages which are sentinel cells of the lung. Activated macrophages release 
cytokines and chemokines to attract neutrophils instantly. Monocytes from blood circulation are 
also recruited to the site of infection and differentiate into macrophages. The professional antigen 
presenting dendritic cells also arrive at the site of infection to phagocytose bacterial antigens, live 
bacteria or dying cells by efferocytosis which later to be transferred to the lymphatic system and 
draining lymph nodes. Since each type of cells’ killing effector functions varies, the survival of 
Mtb differs in these cell types as the fate of the infected cell. All things considered, the initial 
response of these innate cell types is insufficient for the control of Mtb replication which occurs 
exponentially until the adaptive immune response call into action. The onset of adaptive response 
fully potentiates effector functions of infected macrophages which can control the bacterial 
replication. CD4+ Th1 lymphocytes have been thought to be a principal component of adaptive 
immunity to TB. However, B lymphocytes, CD8+ T lymphocytes, Th17 lymphocytes, regulatory 
T lymphocytes and other non-canonical T cells (iNKT cells, group I CD1- restricted T cells, 
mucosal associated invariant T cells and γδ T cells) appear to have a more appreciated role in TB 
immunity. The actual role of these cells and definite percentage of these cell populations required 
for resolution versus immunopathology is still needed to be studied elusively [42].         
Many different cell types act in concert or adversely to each other in granulomas which affect 
the fate of the pathogen within and host immunopathology. Initial studies of an autopsy on human 
TB patients categorized the granulomas into several distinct subtypes. The canonical TB 
granuloma is made up of organized macrophages, neutrophils enclosed by fibroblasts, epithelioid 
macrophages, multinucleated giant cells and a ring of lymphocytes in outside layer. The center of 
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granuloma may contain caseum which is a coagulated necrotic tissue material with its crumbly, 
cheese like white appearance on gross examination. If the mycobacterial replication is controlled 
by the host, the formation of caseum stops, the calcification, and fibrosis of the granuloma takes 
place over time. The necrotic, soft caseum is generally overladen with high numbers of bacteria. 
Enlargement of caseum, transformation into a liquefactive form of caseum, the breakdown of 
surrounding tissue, cavitation, deterioration into airways, dissemination of the bacilli and 
facilitating transmission into new hosts correlate with the progress of tuberculosis [43]. 
Foamy macrophages are specialized macrophage subsets that also appear in tuberculosis 
granulomas. Since their intrinsic abundance of lipid droplets, foamy macrophages serve as a 
nutrient source for Mtb. It is also known that phagolysosome maturation is delayed and the innate 
response is dampened due to polarizing towards alternatively activated phenotype in foamy 
macrophages which provides a safe haven for persistent bacilli phenotype [44]. Electron 
microscopy showed that Mtb-containing phagosomes move towards lipid bodies in foamy 
macrophages and lipid bodies can also contain bacilli. The formation of foamy macrophages can 
be driven by oxygenated mycolic acids and trehalose dimycolate from the bacilli [45]. 
Multinucleated giant cells are another population that can be found in TB granulomas. 
Multinucleated cells are formed by macrophage fusion and lipomannan derived from 
mycobacterial cell wall triggers multinucleation of macrophages [46]. It is proposed that these 
cells have reduced the ability to phagocytose mycobacteria, restriction on cell-to-cell spread of the 
bacilli and role in latency. Macrophages can also undergo distinct transformation into epithelioid 
cells which have firmly interlocked cell membranes to link neighboring cells. These cells are 
thought to make granuloma as effective containing structures. The role of epithelioid macrophages 
in Mtb fate and lesion outcome still needs to be studied. 
There are a few host factors discovered to play role in granuloma formation. CXCR3 signaling 
on polymorphonuclear neutrophils (PMN) notably through MIG (CXCL9) partly controls early 
granuloma formation in low-dose aerosol infected C57BL/6 mice. CXCR3 -/- mice and PMN 
depleted mice had delayed and impaired granuloma formation without an impact on bacterial loads 
and survival. The role of CXCR3 signaling in granuloma formation is transient or complemented 
by other signaling mechanisms in later stages of infection; since CXCR3-/- mice are observed to 
have normal granulomatous responses in chronic TB  [47]. Tissue residing non-hematopoietic 
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epithelial cells are also shown to act in early granuloma formation by augmenting matrix 
metalloproteinase (MMP-9) secretion in combination with infected macrophages in transparent 
 
Figure 1.1: Different stages of tuberculosis immunology and pathology. (A) After Mtb 
(red rod) makes its way to alveoli, it is engulfed by an armada of sentinel alveolar macrophages 
(blue) and neutrophils (orange) in alveolar space and dendritic cells in epithelial lining. Dendritic 
cells are professional antigen presenting cells which migrate into draining lymph node to initiate 
adaptive immune responses. (B) During latent tuberculosis infection (LTBI), highly structured 
solid granulomas are formed that Mtb is contained in mononuclear phagocytes in the central and 
lymphocytes on the periphery. (C) In the course of active TB, granulomas disorganized and central 
necrosis occurs which leads to the formation of caseous granuloma. Subsequently, Mtb can easily 
replicate in caseum, spread to other organs through the bloodstream and spread to the environment 
through rupture into alveolar space [48].  
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zebrafish larvae.  It is hypothesized that by inducing monocyte migration into infection site through 
MMP-9 secretion from epithelial cells and infected macrophages, the permissive growth niche for 
mycobacteria is formed which leads to granuloma maturation and bacterial survival [49]. Data 
from MMP-9-/- mice also confirm that it is required for early recruitment of macrophages through 
MCP-1 (CCL2) signaling, tissue remodeling and eventual maturation of granulomas [50]. Tumor 
necrosis factor alpha (TNF) plays a critical role in the formation and stability of granulomas in 
murine studies contributing to uncontrolled bacterial growth [51]. Macaque studies revealed that 
TNF is more important in intra-granulomatous events like macrophage activation and chemokine 
production rather than formation or maintenance of granulomas [52]. The diverse macrophage 
response effects of TNF are in coordination with interferon-γ (IFNγ) including controlling 
autophagy and release of antimicrobial peptides (i.e. cathelicidin and β-defensin 4) to curtail Mtb 
replication. The other key role of TNF is deciding the cell death fate of infected macrophages in 
granulomas. In initial stages of granuloma formation, mycobacterial ESX-1 secretion system 
mediated apoptosis is in favor of mycobacterial dissemination through recruitment and infection 
of monocytes. However; attenuated Mtb strains (H37Ra, BCG and attenuated live Mtb vaccine 
MTBVAC) are unable to promote colonization of newly recruited cells into granulomas [53].  In 
later stages of solid granulomas or during latent infection, there is clinical evidence that the role 
of TNF is skewed through the host advantage that anti-TNF neutralization therapies in latently 
infected rheumatoid arthritis patients result in TB reactivation [54]. Excessive levels of TNF can 
increase susceptibility to Mtb infection through reactive oxygen species (ROS) mediated 
programmed necrosis or necroptosis which illustrates that TNF is the crucial mediator of 
inflammation and bacterial clearance in tuberculosis immunopathology [55].   
It is regarded that latently infected individuals harbor fibrotic granulomas conventionally; 
whereas TB patients develop necrotic and liquefied granulomas. Non-human primate models of 
tuberculosis unraveled that these temporal changes might be more subtle and nonlinear. Recent 
research on cynomolgus macaques demonstrated a spectrum of granulomas in latent infection with 
necrotic types and non-necrotizing, fibrocalcified granulomas in macaques with clinically active 
TB [56]. Furthermore, individual granulomas behave differently within the same host.  It is 
suggested that bacterial numbers in each granuloma can differ significantly within a single 
macaque. Animals with active disease and latent infection have similar killing effector potential 
in individual lesions, but there is a predominance of lesions of extensive pathology with limited 
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killing functions in macaques with active disease [57]. There are still many unknowns about the 
factors that drive the fate of each granuloma and there is governing view that the outcome of Mtb 
infection is decided on local granuloma level rather than systemic level. It appears that local 
balance of T cells producing IL-10 in combination with T cells producing IL-2, TNF or IL-17 is 
associated with sterility and limit tissue pathology in macaques [58]. It should also be equally 
considered that diverse bacterial populations can exist in different granulomas which add extra 
complexity to elucidate heterogeneity in TB lesions. 
Plasticity and flexibility are the key features of macrophages. Mtb infection alters the 
transcriptional and functional landscape and polarizes them towards classical phenotype. 
Classically activated macrophages activate their antimicrobial effector functions and facilitate Th1 
response by releasing pro-inflammatory cytokines like TNF, IL-12, and IL-1. As it generally 
occurs in the immune system, classical activation is counterbalanced by alternative activation of 
macrophages which are poorly associated with antimicrobial functions. However; alternatively 
activated macrophages are primal for wound healing and resolution [59]. Human alveolar 
macrophages in the steady state do not clearly fit into classically or alternatively activated 
macrophage phenotype. They are essential for hoovering and phagocytosing the inhaled bacteria 
which later leads to initiation of the strong inflammatory response, but also they are required for 
dampening of inflammatory signals and resolution of lung inflammation [60].  
Mtb retains many pathogen-associated molecular patterns that can activate Toll-like receptor, 
C-type lectin receptor, and NOD-like receptor signaling which in turn skew the macrophages in 
the classically activated state. Furthermore; it is evident TB granulomas includes both classically 
and alternatively activated macrophages that Arg1high anti-inflammatory macrophages on outer 
layers and iNOS+Arg1low pro-inflammatory macrophages are situated towards the center where the 
bacilli burden is high [61]. It is also hypothesized that the ratio of classically activated to 
alternatively activated macrophages can be predictive of bacterial burden within each granuloma. 
Researchers tested this hypothesis by implementing a computational model to measure granuloma 
polarization ratio by averaging macrophage polarization scores over entire granuloma [62]. 
Although classical macrophage activation skewing Mtb components are relatively well studied; 
there has not been any virulence factor or signaling mechanisms of Mtb that polarizes macrophages 
into an alternative state defined yet. It is also possible that host derives alternatively activated 
macrophages to dampen excessive immunopathology. This phenomenon is partly shown in vitro 
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macrophage BCG infection model in which IL-6, IL-10, and G-CSF can signal in an 
autocrine/paracrine manner to induce Arg1 in macrophages [63].  
 
4. MTB AND MACROPHAGE INTERPLAY 
As it is known at the systemic level, there needs to be balanced response in macrophage level 
that reduced and enhanced inflammatory responses can both favor Mtb replication. The diminished 
response can result in limited activation and antimicrobial functions which can lead to increased 
intracellular bacilli burden. The exaggerated response can stimulate recruitment of Mtb-permissive 
mononuclear phagocytes, excessive cell necrosis and extracellular replication of the bacilli. The 
clearance of bacteria or the permissiveness to bacterial replication is determined by immune 
recognition signals, response to innate and adaptive immune mediators (cytokines and chemokine),  
cell-autonomous effector mechanisms including oxidative and nitrosative stress, acid exposure and 
lysosomal killing, immune and non-immune GTPases, ubiquitination and autophagic clearance, 
antimicrobial peptides,  competition for iron, zinc, manganese, magnesium and copper cations, 
competition for carbon and amino acid metabolism and IDO which is a rate-limiting enzyme in 
tryptophan metabolism (Figure 1.2) [64]. 
Macrophages recognize Mtb by their pathogen-associated molecular patterns or in other words; 
microbe-associated molecular patterns that occur on the plasma membrane, intracellular vesicle, 
and cytosol. Cell membrane pattern recognition receptors include Mannose Receptor, Mincle, 
Dectin-1, Dectin-2, Macrophage C-type Lectin (MCL), DC-SIGN, Scavenger Receptor A, 
MARCO which also bind Mtb to initiate the phagocytosis. Toll-like receptor family receptors that 
recognize Mtb consist of TLR1/TLR2 heterodimer, TLR2/TLR6 heterodimer, TLR4 and TLR9 
(Figure 1.3). In the cytosol, Nucleotide-binding oligomerizing domain-1 (NOD1) recognized 
diaminopimelic acid (DAP) from peptidoglycan fragments, NOD2 recognizes muramyl dipeptide 
and galectin-3 sense β-galactosides. In a recent study, Stimulator of Interferon Genes (STING) 
was discovered to be a receptor for cGMP-AMP which is generated by cGMP- AMP Synthase 
(cGAS) from microbial DNA and transported into cytosol, in turn induces type I signaling [65]. 
Humoral immunity components can also recognize Mtb, cover the bacterial surface, by that 
opsonize the bacilli and bind their receptor in order to promote indirect recognition of Mtb. 
Surfactant protein A (SP-A), SP-D, mannose-binding lectin (MBL) and complement system 
components; C1q, C3, C3b facilitate opsonization of Mtb. If the individual encountered Mtb 
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antigen before through either infection or vaccination, the invading pathogen can also be opsonized 
by specific antibodies which in turn bind Fcγ receptors. Receptor signaling initiates receptor-
mediated phagocytosis, secretion of pro-inflammatory cytokines and chemokines and functioning 
anti-microbial effectors. 
 
 
Figure 1.2: Mycobacterial evasion strategies in macrophages. Mtb is phagocytosed by a 
myriad of recognition receptors and directed to lysosomal degradation through phagosomal 
maturation and acidification. Virulent mycobacteria are known to interfere with maturation and 
phagolysosome fusion. Mtb faces iron starvation once inside the phagosomes; however, can access 
through transferrin receptor in recycling endosomes. Mtb detection by various cytosolic and 
membrane-associated sensors can activate autophagy to eliminate the bacteria through 
encapsulating Mtb-containing compartment or free cytosolic Mtb by a double membrane, i.e. 
autophagosome which later merges with lysosomes [66].  
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          Figure 1.3: Pattern recognition receptors involved in Mtb sensing. Membrane-
associated receptors include Toll-like receptor (TLR), C-type lectin and scavenger receptor 
classes. Cytosolic receptors sense secreted Mtb virulence factors, cell wall components or 
mycobacterial DNA accessed to cytosol after phagosomal rupture by ESAT6. IRF3 and NFκB are 
major transcription factors activated by these surveillance pathways. Inflammasome and 
autophagy activation are also shown as crucial macrophage responses to limit bacterial replication 
[67]. 
Macrophages employ myriad ways of killing processes to ingest invading microorganisms. 
The hallmark of these functions is phagosome maturation that phagosomes interact with lysosomes 
and endosomes resulting in an exchange of solute materials and membrane components. Fusion of 
these organelles allows acidification of pathogen-containing phagosomes through the acquisition 
of v-ATPase hydrogen pumps, accumulation of proteolytic lysosomal hydrolase enzymes and 
reactive oxygen species. Mtb is able to evade killing machinery and contrive to persist in 
24 
 
macrophages [68]. The two essential ways are circumventing acidification of phagosomes and the 
fusion of phagosomes with lysosomes. Although there has been much debate before, it is now 
widely accepted that Mtb escapes phagosomal milieu and translocates to the cytosol [69]. 
Phagosome maturation blocking permits Mtb to thwart lysosomal degradation and downstream 
immunologic events like antigen presentation to mount an adaptive immune response. 
Mtb secreted phosphatases, PtpA and SapM, is shown to block phagosome maturation by 
interfering with host signaling cascades. PtpA is indispensable for the pathogenesis of Mtb in 
macrophages. Host vesicle trafficking protein vesicular protein sorting 33B (VPS33B) was 
captured to be the target of PtpA by immunoprecipitation methods [70]. VPS33B is a subunit of 
Class C vacuolar protein sorting (VPS) complex and dephosphorylation of VPS33B by PtpA 
induces phagosome maturation arrest. Another target of PtpA is subunit H of macrophage v-
ATPase. PtpA binds in a non-catalytic manner and deranges phagosome pump assembly [71]. 
Lysosomes deliver v-ATPase to phagosomes amidst phagosome maturation which regulates 
proton transport across the membrane and decreases phagosomal pH from 6.5 to around 4.5. SapM 
is a lipid phosphatase and it hydrolyzes phosphatidylinositol 3-phosphate (PI3P). PI3P provides a 
signature membrane tagging signal, designating phagosomes into maturation [72]. It is no surprise 
that this evolutionarily successful pathogen developed multiple ways to interfere with the hallmark 
killing mechanism of macrophages.  
 Reactive oxygen species (ROS) are effective microbicidal agents that can kill intracellular 
pathogens. ROS are synthesized by NADPH oxidase (NOX2) which consists of phagosomal 
transmembrane proteins gp91phox, gp22phox, catalytic subunits p40phox, p47phox, p67phox and small 
GTPase Rac1. For NOX2 to be functional all members need to be translocated into phagosome 
and assembly around gp91phox which later transfer electrons from cytosolic NADPH to phagosomal 
oxygen and resulting in superoxide. Superoxide can be converted into active microbicidal agents 
hydrogen peroxide, hydroxyl radicals and peroxynitrite when reacts with reactive nitrogen 
intermediates. NOX2 is a crucial innate response enzyme, still, it has found to be linked with 
macrophage apoptosis which paves the way for adaptive immunity. It has been recently found that 
a GTPase activating protein of Mtb, nucleoside diphosphate kinase (Ndk) interacts with Rac1 and 
blocks NOX2 assembly which in turn increases Mtb survival in phagosomes. nuoG is found to be 
another virulence factor of Mtb which interferes with the NOX2 generation of phagosomal ROS 
and TNF-mediated apoptosis of infected macrophages [73]. 
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To evade adaptive immune surveillance, Mtb targets antigen presentation on macrophages. 
CD4+ T cell activation is mediated through the presentation of Mtb antigenic peptides on MHC II 
molecules that later induces the release of pro-inflammatory cytokines from T cells and enhances 
microbicidal functions of macrophages. A recent paper controversially claimed that cytokine 
diffusion from CD4+ T cells is dispensable for Mtb control in vivo; however direct recognition of 
MHC II-antigen complexes are required. Researchers used MHC II bone marrow chimeras to 
compare bacterial burden in myeloid cells that can be recognized (MHCII+/+) or incapable of 
recognition (MHCII-/-) by CD4+ T cells. In their experimental setup MHCII+/+ cells had the 
significantly lower bacterial burden and CD4+ T cell depletion increased the burden in MHCII+/+ 
cells but not in MHCII-/- cells [74]. The results actually implicate that TB vaccine development 
should focus on augmenting direct recognition of infected cells by CD4 effector T cells rather than 
inducing polyfunctional (multiple cytokine secreting) CD4 effector T cells. Indeed, Mtb has 
developed different strategies to down-modulate macrophage-T cell interaction.     
Attenuated expression of MHC II molecules is the primary strategy of Mtb is to diminish 
antigen presentation and alter CD4 T cell priming. Interestingly, Mtb lysate can downregulate 
MHCII expression, meaning that Mtb viability is not requisite. Cell wall lipoproteins LpqH (also 
known as 19 kDa lipoprotein), LprG and LprA were shown to down-modulate MHC II expression 
[75]. These lipoproteins function as TLR2 agonists and chronic TLR2 stimulation leads to MHC 
II expression inhibition. The most detailed studied one is LpqH that targets and suppresses 
transcription factor C/EBP mediated MHC II transcriptional transactivator (CIITA) expression 
[76]. Intriguingly, the much earlier study found that LpqH is exported from Mtb-containing 
phagosomes through cytosol which would make it available for sustained TLR2 stimulation and 
prolonged MHC II downmodulation [77]. Another Mtb virulence factor, a DNA methyltransferase 
Rv2966c is also shown to target transcription of C/EBP through translocation into the nucleus, 
methylation of non-CG DNA, interacting with histone H3 and H4 tails thereby repressing 
transcription of host protective genes [78]. These evasion strategies are not limited to 
macrophages; a recent study found that Mtb cell envelope associated serine hydrolase Hip1 impairs 
antigen presentation and maturation of dendritic cells which are the professional antigen-
presenting cells [79].   
Along with MHC II gene expression, Mtb also interferes with maturation and trafficking of 
MHC II molecules to diminish antigen presentation. Earlier studies showed that IFN-γ induced 
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cell surface expression of HLA-DR in human monocytic cell line THP-1 was attenuated in Mtb 
infection and this interference occurred in the transport of class II molecules from trans-Golgi 
network to endosomal and lysosomal vesicles [80]. Cathepsin S was later found to play important 
role in maturation and surface expression of MHC II. Cathepsin S is a lysosomal hydrolase that is 
responsible for removal of invariant chain (Ii) and processing into class II-associated Ii peptide 
(CLIP). When THP-1 cells were infected with BCG, IL-10 expression was induced, thereby 
limiting expression of cathepsin S [81]. IL-10 is an anti-inflammatory cytokine that dampens 
excessive Th1 responses to minimize tissue damage. However; overabundant IL-10 expression 
can be favored for Mtb to evade immune responses, the maturational arrest of class II molecules 
in this case. 
Autophagy is a conserved cellular process that digests potentially harmful macromolecules 
and organelles which are not possible to be degraded by proteasomes. It plays a dual role in defense 
against Mtb by both inhibiting intracellular Mtb growth and restricting excessive inflammatory 
responses; in other words antibacterial and anti-inflammatory. Atg5 is one of the central genes in 
the execution of autophagy and by utilizing LysMcreAtg5flox/flox mice (macrophage and neutrophil-
specific deletion of Atg5 gene), researchers concluded that autophagy is bona fide protection 
mechanism against tuberculosis. When infected with Mtb, LysMcreAtg5flox/flox mice showed 
increased release of IL-1α from macrophages, elevated Th17 response, neutrophilic infiltration, 
tissue necrosis and higher bacterial burdens in the lungs compared to littermate controls [82]. IFN-
γ induces Interferon Response Genes (Irg) that are mainly involved in autophagy and reduction of 
intracellular bacillary load. Many autophagic markers are found to be associated Mtb-containing 
phagosomes. Induction of autophagy by starvation increases the acidification and maturation of 
phagosomes [83]. While IFN-γ and TNF-α induce autophagy, Th2 cytokines IL-4 and IL-13 
inhibits starvation-induced autophagy, autophagic phagolysosome maturation and autophagy-
dependent bacterial killing in Mtb-infected human and mouse macrophages [84]. Counteracting 
on autophagy pathway is a means of action for Th2 cytokines to inhibit Th1-mediated protection 
in Mtb infection. Mtb also targets autophagy pathway by its virulence factors. It is shown that 
ESX-1 secretion system is responsible for the arrest of autophagosome maturation in dendritic 
cells [85]. Since autophagy promotes MHC Class I and MHC Class II-dependent antigen 
presentation and activation of T cell responses, targeting autophagy pathway is a valuable immune 
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evasion mechanism for Mtb. Vaccines that are enhancing macrophage autophagy pathway can be 
advantageous against latent TB infection. 
Peroxisome proliferator-activated receptor (PPAR) family is a group of transcription factors 
in the superfamily of nuclear hormone receptors. The family consists of PPARα, PPARβ/δ and 
PPARγ [86]. PPARγ is abundant in alveolar macrophages and the deletion of PPARγ in alveolar 
macrophages results in increased expression of proinflammatory genes, i.e iNOS, IFNγ, Il12p40, 
Ccl3 and Cxcl10 in bronchoalveolar lavage cells [87]. The virulent H37Rv strain induces PPARγ 
upregulation in human monocyte-derived macrophages through mannose receptor which in turn 
increase Il8 and PGE2 production. The knockdown of PPARγ increases TNF production and 
decreases bacterial replication [88]. The increased resistance of PPARγ knocked-down 
macrophages can also occur through reduction of lipid body formation since PPARγ antagonists 
are shown to inhibit lipid body formations in BCG-infected mouse peritoneal macrophages [89]. 
Modulation of PPARγ pathway through selective molecules has been pursued in type II diabetes 
with a recent ongoing interest in host directed adjunct therapies in tuberculosis [90].  
microRNAs are endogenous, small (~22 nucleotides) non-coding RNA species transcribed in 
primary miRNA (pri-miRNA) form in inter- or intragenic regions of the chromosome. They are 
highly conserved among mammals and mediate crucial gene regulatory events by pairing with 
target mRNA of protein coding genes which result in a decrease in mRNA abundance or 
translational efficiency [91]. There are myriad of miRNA targets and functions identified during 
Mtb infection. let-7f is downregulated in Mtb-infected macrophages in ESAT-6 dependent 
manner. let-7f targets a deubiquitinating enzyme A20 which is a negative regulator NFκB activity, 
thereby fine tuning inflammatory signals in infected macrophages [92]. miR-17 is found to 
regulate autophagy by targeting autophagy suppressor Mcl-1 and its transcriptional activator 
STAT3 [93]. miR-155 is also found to regulate autophagy by targeting autophagy suppressor 
protein Rheb and promote maturation of mycobacterial phagosomes [94]. miR-124 targets TLR6, 
Myd88, TRAF6 and TNF in murine alveolar macrophages to alleviate pathogen-induced 
inflammatory responses [95]. miR-132 and miR-26a target transcriptional coactivator p300 which 
is a mediator of IFN-γ response genes in Mtb-infected human macrophages [96]. On the other 
hand, miR-29 is found to directly target IFN-γ transcripts in T lymphocytes and natural killer cells. 
The transgenic mice with sponge miR-29 sequence (miR-29 knockdown mice) show increased 
resistance to BCG and H37Rv strain [97]. miR-223 directly regulates CXCL2, CCL3 and Il6 
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transcript levels which modulate inflammatory cell chemotaxis to lung and ablation of miR-223 
renders mice susceptible to Mtb infection [98]. Modulation of miRNA expression levels during 
Mtb infection can help researchers to discriminate between healthy individuals, latently infected 
or active TB patients in whole blood or sputum samples [99-102]. miRNA mimics and anti-miRs 
(antagomir) based approaches also provide novel options for host-directed therapy. 
Exosomes are small, 30-100 nanometer, extracellular vesicles that can play role in 
communication between cells or in pathogen dissemination. Exosomes can serve as disease 
biomarkers since they can be isolated from various body fluids like serum, bronchoalveolar lavage, 
urine, saliva and they can act on modulation of host immune response [103]. Exosomes released 
from Mtb-infected macrophages can have both innate and adaptive immune modularity activities. 
Over 40 immuno-dominant mycobacterial proteins including antigen 85 complex, ESAT-6, LpqH 
are found in these exosomes which can activate CD4 and CD8 T lymphocytes in vivo [104]. It is 
not well proven yet how naïve T cell activation occurs in vivo, however, the immune modularity 
effects of exosomes can occur by the presence of antigen-loaded major histocompatibility complex 
(MHC) Class II molecules on the surface of exosomes. Mtb infection augments ATP-triggered 
shedding of MHC-II molecules into microvesicles and exosomes which in turn present antigen to 
naïve T cells [105].  Exosomes from Mtb-infected macrophages can also transport mycobacterial 
RNA and biologically active host RNA. Exosomal RNA from Mtb-infected macrophages can elicit 
different immune responses than exosomal RNA from naïve macrophages in recipient 
macrophages. Interestingly Mtb-infected exosomal RNA also induces apoptosis in recipient cells 
possibly through the presence of mycobacterial RNA [106]. Exosomes can also provide cell-free 
vaccine opportunity in TB research since exosomes from Mtb culture filtrate protein treated 
macrophages can have similar efficacy as BCG vaccine and have better protection when boosting 
BCG-primed mice in low dose aerosol infection [107]. Nevertheless, the immune modulatory 
effects of exosomes in human tuberculosis still await further clarification.  
TB pathogenesis is highly controlled by the bacilli’s ability to subvert the macrophage innate 
responses. Mtb uses multiple and even overlapping strategies to hide and replicate within the 
human host. Manipulation of the macrophage response to Mtb is a promising new avenue for the 
treatment of infection and development of vaccines.
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CHAPTER II 
TRANSCRIPTOMICS OF MTB INFECTED MACROPHAGES 
1. ROLE OF FUNCTIONAL GENOMICS TO UNDERSTAND IMMUNE 
RESPONSES 
Whole genome sequencing of organisms, advancements in microarray technologies, RNA 
sequencing and proteomics have offered to scrutinize complex interactions in the cells that control 
essential biological processes. The emergence of “big data” has revolutionized the view in 
molecular biology from reductionism to non-reductionist systematic view of biological 
phenomena in the last decade. Reductionism tries to reduce the characteristics of a living organism 
to simpler constituents, as it was applied in early years of molecular biology. However; the 
biological phenomenon can only be explained as long as the components and the physiochemical 
interaction between these components are defined with unambiguous axioms [108]. As the popular 
statement indicates that the scientists are becoming to know “more and more about less and less”. 
The colossal information gathered from various –omics technologies brings about the challenging 
question how best to understand complex biological systems. A new field, systems biology, has 
emerged as a consequence of -omics revolution to handle high-throughput data which in turn can 
yield an in-depth understanding of complex cellular networks.  
The research in innate immunity has increased immensely to understand its importance as the 
first line of defense against infectious pathogens and elucidate its intricate interactions with the 
adaptive immune system which made the immunologists realize that innate responses are tightly 
regulated. Innate immunity is a complex network of signal transduction pathways which are 
activated by various stimulators rather than a small set of pathogen recognition receptor pathways 
[109]. A single ligand can activate various signal transduction cascades, albeit it is hardly proven 
that a pathogen can bear single ligand to establish infection. Conventionally, multiple ligands can 
bind to various receptors simultaneously and induce several signaling pathways. These pathways 
frequently cross-talk, regulate each other through positive and negative feedback loops and display 
diverse regulatory mechanisms [110]. Transcription factors form a regulation network to activate 
transcription of specific response genes downstream of these pathways. The significance of post 
transcriptional regulation; e.g. RNA splicing, polyadenylation, RNA editing, micro RNAs and 
long noncoding RNAs mediated regulation, and post translational regulation; e.g. ubiquitination, 
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phosphorylation, acetylation, glycosylation, and proteolysis, are also becoming increasingly 
appreciated. The physiological location and the environment of innate cells can also affect their 
responses to stimuli to a great extent. Stimulation by various cytokines and chemokines, growth 
factors or small lipid signaling molecules, and contact by neighboring immune and non-immune 
cells can have a profound effect on innate responses [111]. The presence of single nucleotide 
polymorphisms (SNP) can change the expression levels of specific genes or protein-protein 
interactions which add an extra layer of complexity in innate immunity at population genetics level 
[112]. The innate immune response does not solely depend on the regulatory pathways in host 
immunity. The pathogen can induce many virulence factors or alter its phenotype to resist in harsh 
environments. It is known that there are distinct differences in the whole transcriptome when 
macrophages are encountered with viable and nonviable Mtb underlining the fact that viable Mtb 
manipulating host responses through various virulence factors [113]. The interaction of Mtb with 
host microbiome can also change the innate response exhibited by the host [114]. The complex 
nature of innate immunity entails an elaborate and in-depth analysis presented by diverse systems 
biology techniques, in a nutshell. Systems biology includes approaching the scientific question in 
genomic, epigenetic, transcriptomic, proteomic, metabolomic, and interactomic level, collecting 
the data in a scientifically sound manner, incorporating bioinformatics and computational biology 
approaches and scrutinizing the perturbations in biological systems. 
Whole transcriptome microarrays and RNA sequencing (RNA–Seq) are routinely used to 
analyze gene expression profiling. Microarrays have been the benchmark method to measure the 
gene expression levels simultaneously in a specific cell population, though they are limited by the 
probes deposited on the microarray chip. The seminal paper in tuberculosis field employing 
microarray is the first comparison of whole blood transcriptome of healthy individuals and active 
tuberculosis patients which revealed previously underestimated neutrophil driven Type I 
Interferon signaling in TB patients [115]. Rapid genome-wide sequencing provided by next 
generation sequencers have become favorable in recent years. In a recent South African study, the 
blood samples of latently infected adolescents were collected every 6 months and disease 
progression was monitored prospectively [116]. Whole blood transcriptome through RNA-Seq 
revealed a 16-gene disease progression signature which can be used a diagnostic tool to predict 
which latently infected individual is more likely to progress active TB. The full transcriptome 
sequencing approach remains expensive, demands rather larger amount of RNA and necessitates 
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a validation step through quantitative PCR (qPCR) for genes of interests. As in delineation of TB 
biomarkers, a signature panel of genes is tolerable rather than complete transcriptome to handle 
specific questions. Therefore, high throughput multiplex gene expression systems like Fluidigm 
and nCounter can offer cheaper alternatives to full transcriptomics approaches with low amounts 
of sample in TB diagnostics [117].  
Transcriptomics at a single cell level brought attention to the matter of heterogeneity in 
homogenous populations that were considered to be uniform. Single cell RNA sequencing 
(scRNA-Seq) can allow the study of rare cell populations in the immune system by clustering 
whole transcriptomics profiles of immune cells and cataloging similar sets [118]. scRNA-Seq on 
bone marrow-derived dendritic cells revealed that there is considerable bimodality in gene 
expression, alternative splicing and regulatory circuit activation in response to lipopolysaccharide 
(LPS) [119]. These previously unobserved levels of heterogeneity can reveal new cell states and 
markers that can differentiate within the seemingly homogenous population. The limiting factor in 
scRNA-Seq is that processing of single cells is relatively time-consuming which require various 
sequential methods, hence the risk of batch effect. The scalability of scRNA-Seq has been 
dramatically improved by utilizing droplet micro fluidics in which single microparticles coated 
with poly (T) barcodes and single cells encapsulated together in nanoliter-scale droplets [120].  
Recent breakthroughs with next generation sequencing and the establishment of large 
sequencing consortiums such as Encyclopedia of DNA Elements (ENCODE) or Functional 
Annotation of Mammalian Genome (FANTOM) unveiled substantial numbers of non-coding 
RNAs in mammalian genome [121, 122]. microRNAs are usually profiled with small RNA 
sequencing or specific miRNA arrays, and later miRNAs of interest are validated by qPCR. 
Profiling of circulating miRNAs in serum in Chinese cohort identified numerous miRNAs that are 
differentially expressed, with mir29a as the most promising marker, between active TB patients 
and healthy controls [123]. Increasing availability and affordability of miRNA profiling and 
growing interest in TB field has deemed miRNAs as potential biomarkers and targets of 
therapeutic interventions [124]. Another non-coding RNA species in the spotlight is long non- 
coding RNAs (lncRNA) which are longer than 200 nucleotides, expressed in nearly all cell types 
and regulates transcription, splicing, RNA degradation, translation and epigenetic modifications 
[125].Profiling of lncRNA expression generally rests on data from RNA-Seq to choose lncRNAs 
of interest followed by qPCR step. These studies have led to numerous roles of lncRNAs in 
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immunity including differentiation and activation of T cells, regulation of innate response, 
differentiation of monocytes into macrophages and dendritic cells, chromatin remodeling during 
variable, diversity and joining (V(D)J) in antigen receptors in T and B lymphocytes [126]. In terms 
of lncRNAs in host-pathogen interactions lncRNA-CD244 is found to be upregulated in 
CD244+CD8+ T cells during active disease. CD244 is a costimulatory molecule and modulates 
IFNg and TNF release from CD8+ T cells through upregulation of lncRNA-CD244 levels. 
LncRNA-CD244 is shown to recruit polycomb protein enhancer of zeste homolog 2 (EZH2) to 
promoters of IFNg and TNF leading to trimethylation at H3K27 and repressive chromatin states 
[127]. In a recent study, maternally expressed gene 3 (MEG3) lncRNA is shown to negatively 
regulate IFNg induced autophagy in BCG infected macrophages [128]. Genetic deletion of 
LncRNA-EPS (lncRNA-erythroid pro-survival) in mice revealed that lncRNA acts as a 
transcriptional repressor of IRGs (immune response genes) in macrophages in response to LPS 
stimulation by recruiting ribonucleoprotein complexes to promoters of its target genes [129]. 
Epigenetics relate to long-term or heritable changes in gene expression which can change the 
phenotype without altering genotype of the cell. Epigenetics profiling is routinely performed by 
chromatin immunoprecipitation (ChIP) which is to precipitate modified histones by specific 
antibodies and analyze DNA sequences that are bound to histone complexes. Another widely used 
epigenetics method in immunology is DNAse hypersensitivity assay to detect loosely packed 
genomic sites by nucleosomes with the concept that active transcription occurs in hypersensitive 
sites. Integration of these techniques with next generation sequencing methods advanced the 
sensitivity and specificity of uncovering epigenetic modifications in a given cell state. The 
significance of epigenetics in regulating immune response has been established in recent reports. 
It is shown that after BCG vaccination monocyte phenotype is changed through H3K4 
trimethylation on the promoters of several cytokines and immune activation genes and these 
“trained” monocytes respond better to unrelated pathogens such as Candida 
albicans and Staphylococcus aureus [130]. In a recent effort, genome-wide methylation sites are 
mapped in Mtb infected human monocyte derived DCs. The data suggests that there is a strong 
demethylation pattern occurring in distal regulatory elements, mainly in enhancers of key 
transcription factors of the innate response, e.g. REL, NFKB1, IRF2, and IRF4 [131]. H3K4 
monomethylation ChIP Sequencing in Mtb infected macrophages revealed that Alu repeats 
(ancestral short interspersed elements) are enriched in these enhancer regions and contain putative 
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transcription factor binding sites for MEF2, ATF, LXR and RAR which are involved in 
macrophage differentiation, survival and response to infection [132]. Deciphering of epigenetic 
factors or markers that are involved in Mtb pathogenesis can be key to understand immune 
modulation and pave the way for novel therapeutic interventions or biomarkers. 
With the advent of next-generation sequencing methods and their decreasing costs, there is an 
increasing number of datasets that harbor exhaustive host and pathogen genome sequences. These 
datasets can be mined to pertain genomic information to immune system functions. Genome-wide 
association studies (GWAS) compare genomic sequences to find a relation between single 
nucleotide polymorphisms (SNP) and specific traits such as disease outcome.  There have been 
many studies that are linking polymorphisms in host innate immune genes, e.g. major 
histocompatibility complex (MHC), tumor necrosis factor (TNF) and its associated receptors, toll 
like receptors, vitamin D receptor (VDR), soluble C-type lectins, cytokines and chemokines to 
host susceptibility to TB [133]. Despite genetic association studies have partly explained why 
some individuals are more susceptible to TB, they do not report the underlying mechanisms. ChIP 
assays can be helpful to pinpoint whether these polymorphisms are on regulatory sites such as 
transcription factor binding sites. Accordingly, there has been increasing interest in expression 
quantitative trait loci (eQTL) which influence the gene expression, as a greater number of 
polymorphisms associated with diseases map to regulatory regions in lieu of protein coding regions 
[134]. Mapping of eQTL in Mtb infected primary human dendritic cells identified dual-specificity 
phosphatase 14 (DUSP14), receptor-interacting serine/threonine-protein kinase 2 (RIPK2) and V-
type proton ATPase 116 kDa subunit an isoform 2 (ATP6V0A2) as novel candidates to affect 
susceptibility to TB [135]. Dissecting eQTLs can help to understand molecular mechanisms which 
may be an important weapon to fight against TB.  
2. CAP ANALYSIS GENE EXPRESSION (CAGE) SEQUENCING 
  Quantifying transcript abundance is a fundamental approach to investigate gene regulation, 
the molecular principle of complex biological systems. RNA-Seq and CAGE-Seq are two major 
technologies that have emerged with next-generation sequencing platforms to measure transcript 
abundance. The advantage of RNA-Seq over CAGE-Seq is that full length of RNA sequence can 
be identified since RNA-Seq focuses on sequencing random fragments of RNA or cDNA which 
are later mapped to reference transcriptome. RNA-Seq allows alternative splicing and gene fusion 
discovery as an upper hand over CAGE-Seq. On the contrary, CAGE is devised originally to 
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construct full-length cDNA libraries by identifying 5’ ends of capped RNAs through chemically 
labeling with biotin residues which was termed cap trapping [136]. Initially, CAGE sequencing 
protocol was consisting of cDNA synthesis with oligodT primers, cap trapping of full length 
cDNAs with linkers (contains recognition site for restriction enzymes) attached to 5’ ends, 
digestion with class II restriction enzymes where they cleave 20 nucleotides downstream of the 
recognition site, amplification of these tags by PCR, ligation of the tags to form concatamers, 
cloning into plasmids followed by Sanger sequencing method [137]. cDNA synthesis with oligodT 
primers was later changed with random primers to detect non-polyadenylated RNA transcripts 
(Figure 2.1). CAGE Sequencing allowed precise mapping of transcription start sites (TSS) and 
their associated core promoters by its very nature. However; with Sanger sequencing only 
approximately 48500 tags per mouse cell were sequenced which was not reflecting the complexity 
of the transcriptional landscape. Conventional sequencing method was changed with high 
throughput sequencer from 454 Life Sciences which did not require cloning of concatamers in 
bacteria and DeepCAGE method was developed. DeepCAGE on hippocampus dramatically 
increased the sampling depth with 1.4 million tags mapped to mouse genome [138]. Over the years, 
CAGE sequencing was improved by introducing EcoP15I restriction enzyme which cleaves 27 
nucleotide downstream thereby increasing CAGE tag lengths and their mapping efficiency to 
reference genome. Optimization of linkers and ligation reactions decreased required RNA amount 
from 50 μg to 1-5 μg and it was adapted to Illumina Sequencers. Barcoding of CAGE linkers 
allowed to pool 4 to 6 libraries to a single lane and reduced cost of sequencing [139]. CAGE 
method was further simplified when it was adapted to third generation sequencer from Helicos 
Biosciences. The single molecule sequencer, HeliScope Genetic Analyses, avoids PCR 
amplification of CAGE tags, thereby preventing potential biases introduced during library 
production. HeliScopeCAGE also does not need second strand synthesis of cDNA that it directly 
sequences poly(A) tailed single strand cDNA for the first time [140]. The HeliScopeCAGE 
protocol has been broadly employed in Functional Annotation of Mammalian Genome 5 
(FANTOM5) project in order to provide transcription initiation network over 1000 mammalian 
cells. FANTOM5 can provide transcriptional initiation activities in a single base pair resolution 
from very diverse states of mainly primary human and mouse cells [122]. The extensive profiling 
across samples allows digging up genes, transcription factors, and noncoding RNAs and analyzing 
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their activation states across biological states. TSS profiles also provide the opportunity to 
correlate transcription factor activity with motifs and epigenetic features when it is compared with 
               
Figure 2.1: Procedure of CAGE protocol. RNA is reverse transcribed into cDNA with random 
primers. Both ends of cDNA are later biotinylated which is followed by RNase I treatment. RNase 
I is not effective against RNA-cDNA hybrids, however, it cleaves single stranded RNAs and 
biotinylated 3’ end is removed from RNA-cDNA hybrid. Biotinylated RNA-cDNA hybrid is 
captured on streptavidin beads and single stranded DNA (ssDNA) is purified after Tris-HCl 
neutralization and fractionation. ssDNA is later ligated to biotinylated CAGE linkers which 
introduce MmeI recognition site to 5’ end of ssDNA. The second strand of ssDNA is synthesized, 
followed by MmeI digestion of double stranded DNA. MmeI digestion creates 2bp overhang which 
is optimal for ligation of a second linker containing XmaJI recognition sites. Double stranded 
CAGE construct is amplified by PCR and later digested by XmaJI which leads to compatible ends 
for concatenation of CAGE tags. Concatamers are subsequently cloned into plasmids and finally 
sequenced under conditions befitting to GC-rich regions and secondary structures[141].   
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available ChIP-Seq data. FANTOM5 CAGE Expression Atlas also provided the means to catalog 
enhancers by virtue of the fact that RNA Polymerase initiates the transcription in enhancer regions 
bi-directionally and CAGE can detect balanced bi-directional capped RNAs which reveals 
enhancer activity [142]. 
3. EXPERIMENTAL DESIGN and REFINEMENT of CAGE DATA 
Mouse bone marrow-derived macrophages (BMDM) are used to investigate the changes in the 
transcriptional landscape of the host after infection with clinical hypervirulent HN878 Beijing 
strain of Mtb. BMDMs are primary macrophages which are derived from bone marrow cells in the 
presence of a specific growth factor macrophage-colony stimulating factor (M-CSF). They are 
widely used in immunological studies because of the high yield and relatively homogenous 
population. We also scrutinized whether activation states of macrophages can alter their response 
to Mtb infection. BMDMs are stimulated with IFNg to direct them towards M1 polarization 
(classically activated macrophages, caMph) and IL-4, IL-13 or in a combination of IL-4, IL-13 for 
M2 polarization (alternatively activated macrophages, aaMph). Total RNA was extracted in an 
extensive time-kinetic manner from both infected and non-infected macrophages (Figure 2.2).  
Initially, the goal was to obtain four replicates for each time point and macrophage state. 
Unfortunately total RNA of infected samples from replicate #3 and non-infected samples from 
replicate #4 was not sequenced because of the experimental drawbacks. Furthermore; a few 
libraries had less than 500.000 total tags which were removed from analysis to meet library depth 
criteria since shallow libraries can produce false positive gene expression data [122] (Table 2.1). 
The full FANTOM5 mouse CAGE transcriptome consists of 158966 tags that are mapped to 
the mouse genome (Figure 2.3). From these tags, nearly 22.5% of them have TPM value over 10 
in at least one mouse-Mtb infection dataset.  Out of 35791 tags, nearly 54% of them were annotated 
to a gene or a transcript by FANTOM5 consortium through comparing with gene models from 
UCSC RefSeq, UCSC known gene, ENSEMBL transcripts and full-length mRNA tracks from 
UCSC genome database [122]. From nearly 19300 CAGE clusters, around 25% of them showed 
differential expression at 4 hours and 24 hours post infection in three different Mtb infected 
polarization states (non-stimulated, IFNg stimulated and IL4/IL13 stimulated). To simplify the 
analysis, these three different polarization states with their Mtb infection and non-infection 
datasets are used in this Chapter. The unannotated tag clusters generally have low TPM values and 
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lower proportion (10.6%) of them showed differential expression compared to annotated tags. 
When the differentially expressed (DE) clusters are looked into carefully, there is no skew towards 
upregulation or downregulation of CAGE clusters. In annotated DE CAGE tags 47.3% of them 
are upregulated; however, 56% of DE tags are upregulated in unannotated CAGE clusters. 
 
 
 Figure 2.2: Layout of CAGE Experiment. Bone marrow cells from male BALB/c 
background mice are differentiated into BMDMs in M-CSF conditioned media for 10 days in vitro. 
BMDMs are harvested and seeded overnight in 6-well plates at 3x10^6 cells/well density. They 
are either left untreated or stimulated with recombinant mouse IFNγ (100U/ml), IL-4 (100U/ml), 
IL-13 (100U/ml) for overnight. They are infected with HN878 Mtb strain with a multiplicity of 
infection (MOI) 5 or left uninfected (uninfected macrophages are not shown in the figure for 
simplicity). Total RNA at 0hr, 4, 12, 24, 48 and 96 hours post infection is extracted for CAGE 
sequencing. These experiments were performed by Dr. Sugata Roy, Dr. Anita Schwegmann, and 
Dr. Reto Guler.   
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 Table 2.1: Missing datasets from transcriptomics analysis. Tick denotes the presence 
of full dataset in corresponding macrophage state. Time points shown are the missing datasets for 
that replicate and macrophage state. 
  Unsupervised hierarchical clustering of samples shows a distinct grouping of infection and 
non-infection samples except Mtb infection in non-stimulated macrophages at 24 hours post 
infection time point (Figure 2.4). In uninfected samples there is no strong pattern of clustering; 
however, there is a tendency that same polarization states cluster together. Interestingly, the 
clustering pattern differs at early time points after infection, i.e. the expression profiles at 4 and 12 
hours post infection cluster together and not based on the polarization states. In later time points, 
it appears that IL4/IL13 stimulated Mtb infected samples and IFNg stimulated Mtb infected 
samples cluster within their group. PCA analysis of Mtb infection samples also revealed that early 
time points after infection tend to cluster together regardless of their stimulation state (Figure 2.5). 
24 hours post stimulation (or 0h of infection) samples are clustered more closely than any other 
time point and as the infection progresses over time the samples that belong to same time point 
start to group away from each other. At later time points of infection, the samples look to cluster 
according to their polarization states rather than the time point group that they belong to which is 
also observed in heatmap figure.    
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 Figure 2.3: Refinement of CAGE tags. The full mouse-Mtb infection dataset is first 
filtered by removing out lowly expressed tags in all time points and activation states. Differential 
expression analysis is performed in Mtb infected non-stimulated, IFNg stimulated and IL-4/IL-13 
stimulated samples compared to the non-infected counterparts. 
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Figure 2.4: Unsupervised hierarchical clustering of Mtb infected and uninfected 
samples and heatmap of tag clusters. TPM values for each tag from replicate #1 (Rep1) and 
replicate #2 (Rep2) are averaged (replicate #3 does not have infection data and replicate #4 does 
not have non-infection data, see Table 2.1). Each row represents the individual tags with blue 
gradient showing downregulation and red gradient showing upregulation of these tags in 
corresponding samples. Unsupervised hierarchical clustering and heatmap are constructed by 
using HierarchicalClustering and HeatMapViewer modules in GenePattern [143]. 
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 Figure 2.5: PCA Analysis of Mtb infected samples. Total CAGE tag expression values 
for Rep1 and Rep2 are analyzed for PCA in MultiExperiment Viewer (MeV) [144]. “●” represents 
Rep1 samples and “▼” represents Rep2 samples. Non-stimulated Mtb infected samples are shown 
in green, IFNg stimulated Mtb infected samples are shown in yellow and IL4/IL13 stimulated Mtb 
infected samples are shown in blue color. 0h, 4h, and 12h samples are encircled to show close 
clustering.   
 
4. TRANSCRIPTIONAL CHANGES INDUCED by HN878 INFECTION  
The infection of primary murine macrophages with hypervirulent Mtb strain changes the 
full transcriptome drastically at earlier time points, i.e 4 hours and 12 hours post infection (Figure 
2.6).  Although there are more downregulated tags than upregulated tags (3319 tags vs 3272 tags), 
the mean log2 fold change in early time points is over 0 meaning that the combinatorial magnitude 
of upregulation surpasses the combinatorial magnitude of downregulation. To give an example, 
interleukin-6 (Il6) is one of the highest upregulated genes with nearly 2400 fold induction at 4 
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hours post infection in IFNg stimulated macrophages and cannabinoid receptor 2 (Cnr2) is one of 
the highest downregulated genes with over 170 fold reduction at 4 hours post infection in non-
stimulated macrophages. Mtb infection initiates such a drastic change in macrophage 
transcriptome (around 40% of annotated tags show common differential expression) that different 
macrophage states behave in similar fashion at transcriptional level (Figure 2.7). However; only 
5.7% of unannotated tags (100 out of 1751) display common DE characteristic which implies that 
the response of these macrophage states can differ substantially in unannotated noncoding RNAs 
or unannotated alternative isoforms of coding RNAs. 
 
 
 Figure 2.6: Fold change (FC) distribution of CAGE tags. Under three different 
stimulation conditions, the fold changes for each individual tags are calculated by comparing Mtb 
infected and non-infected samples at specified time points by averaging replicate #1 and replicate 
#2 TPMs. Log2 FC values are drawn as a box-whisker plot with whiskers covering 1-99 percentile. 
Values below or above the percentile range are staggered as individual dots. The line in the box 
shows median value and “+” denotes mean value.    
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Figure 2.7: Venn diagrams of differentially expressed tags. Differentially expressed 
tags meeting threshold criteria (fold change ≥ 2, multiple comparisons testing with p < 0.05 and 
false discovery rate < 5%) are determined for annotated tags (left) and unannotated tags (right) for 
4 hours and 12 hours post infection datasets compared to 0 hr dataset in three different macrophage 
states. Venn diagrams are constructed with Venny tool [145]. 
 
Additionally, the genes that respond the strongest to Mtb infection in each macrophage 
activation states are assessed. As expected, many cytokines and chemokines associated with the 
innate immune response including interleukin-6, inhibin B, Cxcl1, Cxcl2, Cxcl3, vascular 
endothelial growth inhibitor (Tnfsf15), interleukin-1 alpha, granulocyte colony stimulating factor 
(Csf3), interleukin-12 alpha and interleukin-27 were amongst the highest upregulated genes (Table 
2.2). Prostaglandin synthase 2, endothelin 1, tissue factor (F3), signaling lymphocytic activation 
molecule (Slamf1), oxidized low density lipoprotein receptor (Olr1) and Phldb1 are also associated 
with various aspects of innate immune response; hence it is not surprising to find them in 
upregulated gene list. Whereas the strongest downregulated genes (Table 2.3) include various 
signal transduction genes (Sesn1, Rnf144b, and Lyl1), G-protein coupled receptors (Cnr2, Lpar5) 
and histone proteins (His1h3b and His1h3c) except a cytokine CD4+ cell chemoattractant Il16 and 
chemokine receptor Ccr2 [146].   
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 Table 2.2: Highest upregulated genes common in three polarization states of 
macrophages after Mtb infection. Fold change shown in the table corresponds to highest fold 
change in early time points (4h and 12h pi) when the TPM values are averaged over replicates. 
The short molecular function of the genes is retrieved from UniProt database [147]. 
 
   
 Non-stim macrophages IFNg-stim macrophages IL4IL13-stim macrophages 
Tag Name Molecular 
Function 
TPM Fold 
Change 
p-value TPM Fold 
Change 
p-value TPM Fold 
Change 
p-value 
p1@Edn1 Vasoactive, 
vasoconstrictor 
0.5 2208 4.4E-25 0 3051 1.8E-18 0.5 3699 6.5E-22 
p1@Ptgs2 Dioxygenase, 
oxidoreductase 
7.8 1979 8.5E-30 26.2 1059 1.7E-18 11.9 1912 4.8E-23 
p1@Il6 Cytokine, 
growth factor 
0 1935 4.2E-27 0.9 2470 1.4E-19 0.5 2256 5.5E-20 
p1@Inhba Growth factor, 
hormone 
0 1156 7E-19 0 2557 5.6E-10 0 2579 1.6E-16 
p1@Cxcl1 Cytokine, 
growth factor 
16.2 1064 2.8E-25 9.8 1080 1.4E-16 16.7 1192 1.5E-22 
p1@Cxcl2 Cytokine 35 798 1.9E-24 63.5 729 9.6E-18 39.6 1014 6.5E-22 
p1@Tnfsf15 Cytokine 0 538 1.4E-21 0 1188 1.1E-17 0 553 1.6E-15 
p1@F3 Blood 
coagulation 
0 285 1E-17 0 976 8.6E-17 0 857 3.3E-16 
p1@Il1a Cytokine 1.9 761 1.2E-25 2.5 832 2.4E-18 3.5 730 2.1E-21 
p1@Cxcl3 Cytokine 4.2 539 3.3E-21 3.6 743 6.3E-09 15.4 293 1.8E-18 
p1@Csf3 Cytokine, 
growth factor 
0 518 3.7E-18 0 531 6.4E-14 0 490 3.3E-14 
p1@Slamf1 Receptor 0.5 135 7.2E-13 0 448 1.9E-10 0 828 4.2E-16 
p1@Olr1 Receptor 0 146 6.8E-14 0 174 3.4E-11 0.5 296 1.5E-15 
p2@Il27 Cytokine 0.5 67 6.4E-22 0.4 380 1.1E-17 0 146 8.7E-15 
p1@Phldb1 Cytoskeleton 0 45 6.9E-07 0 76 4E-06 0 104 3E-09 
p1@Il12a Cytokine 0 24 8.3E-10 0 42 3.9E-08 0 104 1.9E-08 
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Table 2.3: Highest downregulated genes common in three polarization states of 
macrophages after Mtb infection. Fold changes shown in the table correspond to lowest fold 
changes in early time points (4h and 12h pi) compared to 0h when the TPM values are averaged 
over replicates. 
Enrichment analysis of common upregulated genes reports anticipated Gene Ontology 
(GO) Biological Terms with high confidence including response to the bacterial origin, positive 
regulation of cytokine response, inflammatory response (Table 2.4). Gene list enrichment analysis 
is performed on a web-based software Enrichr which covers more than 100 gene set libraries 
ranging from metabolic pathways, ENCODE ChIP-Seq data, ontology resources to proteome maps  
[148]. Kinase enrichment analysis is a way to have an idea about which signal transduction 
pathways can be activated after perturbation. Here, we see that there is enrichment in mitogen-
activated protein (MAP) kinase signaling pathways, the master macrophage innate immune 
response cascade NF-κB signaling and interferon regulatory factor 3 (IRF3) signaling (Table 2.5). 
 Non-stim macrophages IFNg-stim macrophages IL4IL13-stim macrophages 
Tag Name Molecular 
Function 
TPM Fold 
Change 
p-value TPM Fold 
Change 
p-value TPM Fold 
Change 
p-value 
p1@Cnr2 Receptor 38.1 -171 4.7E-10 26.9 -54 7.4E-10 62.2 -58 3.3E-08 
p2@Lpar5 Receptor 30.7 -82 2.7E-10 44.7 -89 5E-10 55.3 -99 2.9E-08 
p1@Sesn1 Oxidoreductase 41.9 -67 1.8E-12 72 -143 1.3E-10 87 -165 1.8E-09 
p1@Gcnt1 Glycosyltransferase 98.3 -28 2.4E-09 70.7 -23 2.9E-08 64.6 -9 4E-04 
p1@Ccr2 Receptor 27 -12 4.9E-05 46.9 -94 1.7E-09 32.4 -45 1.7E-07 
p2@Kcnj10 Ion channel 17.4 -40 5.6E-11 28.8 -58 9.4E-10 17.1 -32 5.2E-08 
p1@Rnf144b Transferase 25.5 -31 6.1E-10 24.3 -44 5.3E-09 17.8 -17 7.4E-07 
p1@Susd3 Membrane protein 57.6 -13 8.4E-08 84.2 -42 1.9E-08 68.1 -23 3.1E-06 
p1@Hist1h3b DNA binding 43.9 -6 0.02 17.2 -31 1.8E-08 55.1 -101 1E-12 
p2@Hist1h3c DNA binding 42.3 -19 0.002 12.7 -10 0.035 39.2 -78 2.7E-11 
p1@Il16 Cytokine 16.1 -16 2.2E-09 32.6 -27 1.4E-09 31 -57 7.6E-10 
p1@Lyl1 Transcription fact. 97 -16 3.7E-09 113.1 -28 2.5E-08 127.1 -14 2.6E-05 
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Enrichment analysis of transcription factor binding motifs in the promoters of genes of interest 
revealed that downstream master regulators of NF-κB signaling, i.e. Rela and Nfkb1, and MAP 
kinase signaling Egr1 and Tfap2a can be the major transcription factors that drive the gene 
expression in Mtb response in different macrophage states.       
GO Term Overlap P-value Adjusted 
P-value 
response to molecule of bacterial origin 
(GO:0002237) 
71/243 2.43E-33 1.02E-29 
response to lipopolysaccharide (GO:0032496) 68/228 1.39E-32 2.91E-29 
inflammatory response (GO:0006954) 82/376 1.75E-28 2.45E-25 
regulation of cytokine production 
(GO:0001817) 
88/482 1.14E-24 1.2E-21 
cellular response to lipopolysaccharide 
(GO:0071222) 
41/110 2.55E-24 2.15E-21 
cellular response to molecule of bacterial origin 
(GO:0071219) 
41/116 2.76E-23 1.93E-20 
regulation of response to wounding 
(GO:1903034) 
69/347 1.06E-21 4.94E-19 
positive regulation of defense response 
(GO:0031349) 
61/272 4.08E-22 2.14E-19 
cellular response to biotic stimulus 
(GO:0071216) 
43/132 9.75E-23 5.85E-20 
positive regulation of cytokine production 
(GO:0001819) 
66/327 3.57E-21 1.5E-18 
 
Table 2.4: Top Gene Ontology Biological Process Terms Associated with Common 
Upregulated Genes. Genes that are commonly upregulated at early time points post Mtb infection 
in all three macrophage states are analyzed through Web-based tool Enrichr. Here top 10 most 
enriched GO biological process terms are shown in the table. Fischer’s Exact Test is employed by 
Enrichr to rank the terms and compute statistical significance. Overlap is the ratio of a number of 
genes from the initial gene list inquired that are represented in a single GO term to the total number 
of genes in that specific GO term. 
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Table 2.5: Top Enriched Kinases Associated with Common Upregulated Genes. 
Kinase enrichment analysis (KEA) from Enrichr is employed to detect which kinases and their 
substrates are enriched in commonly upregulated genes at early time points post Mtb infection in 
all three macrophage states. 
Kinase Pathway Associated Overlap P-value Adjusted 
P-value 
Mapk14 p38 MAPK cascade 48/396 9.88E-08 2E-05 
Mapk1 ERK1 and ERK2 cascade 40/326 8.33E-07 5.64E-05 
Tbk1 IRF3 signalling 7/11 3.32E-07 3.37E-05 
Gsk3b Glucose homeostasis 52/527 1.51E-05 7.68E-04 
Cdk2 Cell Cycle 52/553 5.49E-05 0.002 
Ikbkb NF-kB signalling 8/25 3.08E-05 0.001 
Mapk4 Atypical MAPK signalling 9/34 5.33E-05 0.002 
Abl1 Cell growth and survival 15/94 1.31E-04 0.003 
Mapk9 JNK signalling 18/131 2.1E-04 0.005 
Src Cytoskeletal organization 27/259 7.11E-04 0.013 
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Table 2.6: Enriched Transcription Factor motifs with Common Upregulated Genes. 
Enrichr employs position weight matrices from TRANSFAC and JASPAR databases to browse 
through -2000 bp upstream and 500 bp downstream of transcription start site of genes of interest 
to identify putative transcription factor binding sites. Only 7 mouse transcription factors are 
statistically found to be enriched after multiple comparisons test computed by Enrichr.  
As it is seen in the fold changes of perturbed genes after Mtb infection, downregulated 
genes are also not enriched as strong as upregulated genes in terms of the kinase, TF motif 
enrichment and GO biological process terms (Table 2.7-2.9). Kinase enrichment and TF motif 
enrichment analysis report less number of statistically significant targets in downregulated genes. 
Gsk3b and Cdk2 kinases are present in both upregulated and downregulated gene enrichment 
analysis, yet lower coverage in downregulated genes. Another MAPK signaling member, Mapk12 
substrates are found to be enriched in downregulated genes. The TF binding motifs that are 
enriched in downregulated genes are rather intriguing, since none of the four TFs, i.e. Sox10, 
Tead2, E2f1, and Myod1, are closely related to innate immune response.  Interestingly, guanosine 
triphosphate hydrolase (GTPase) activity is over represented along with genes associated with B 
cell regulation and muscle cell differentiation. There are many GTPases that are associated with 
MAPK or NF-κB signal transduction which can explain enrichment of GTPase related terms, but 
hemostasis, DNA damage checkpoint and muscle cell differentiation terms are peculiar to be 
enriched in downregulated genes.  
Transcription 
Factor (TF) 
TF Full  Name Overlap P-value Adjusted P-
value 
Egr1 Early growth response protein 1 147/1617 7.17E-11 1.12E-08 
Smad4 Mothers against decapentaplegic 
homolog 4 
145/1580 5.02E-11 1.12E-08 
Sp1 Transcription factor Sp1 194/2360 2.88E-10 2.99E-08 
Rela Transcription factor p65 134/1656 6.28E-07 3.92E-05 
Nfkb1 Nuclear factor NF-kappa-B 
p105 subunit 
229/3284 6.3E-06 3.28E-04 
Prdm1 PR domain zinc finger protein 1 21/196 0.002 0.039 
Tfap2a Transcription factor AP-2-alpha 115/1663 0.002 0.045 
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Kinase Pathway Associated Overlap P-value Adjusted P-
value 
Cdk2 Cell Cycle 43/553 6.6E-05 0.005 
Mapk12 p38 MAPK cascade 6/15 1.84E-05 0.003 
Gsk3b Glucose homeostasis 38/527 7.5E-04 0.04 
Akt1 Protein Kinase B signalling 19/210 0.001 0.051 
Table 2.7: Top Enriched Kinases Associated with Common Downregulated Genes. 
Kinase enrichment analysis (KEA) from Enrichr is employed to detect which kinases and their 
substrates are significantly enriched in commonly down-regulated genes at early time points post 
Mtb infection in all three macrophage states. 
 
Transcription 
Factor (TF) 
TF Full Name Overlap P-value Adjusted P-
value 
Sox10 Transcription factor SOX-10 41/451 2.49E-06 4.0E-04 
Tead2 Transcriptional enhancer 
factor TEF-4 
94/1591 3.0E-04 0.014 
E2f1 Transcription factor E2F1 163/3056 4.0E-04 0.014 
Myod1 Myoblast determination 
protein 1 
96/1672 7.0E-04 0.023 
          Table 2.8: Enriched Transcription Factor motifs with Common Downregulated Genes. 
Enrichr employs position weight matrices from TRANSFAC and JASPAR databases to browse 
through -2000 bp upstream and 500 bp downstream of transcription start site of genes of interest 
to identify putative transcription factor binding sites. Only 4 mouse transcription factors are 
statistically found to be enriched in common down-regulated genes’ promoters after multiple 
comparisons test computed by Enrichr. 
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Term Overlap P-value Adjusted P-
value 
positive regulation of GTPase activity 
(GO:0043547) 
54/482 3.72E-11 7.19E-08 
positive regulation of GTP catabolic 
process (GO:0033126) 
54/483 4.02E-11 7.19E-08 
regulation of small GTPase mediated 
signal transduction (GO:0051056) 
34/256 2.27E-09 2.71E-06 
small GTPase mediated signal 
transduction (GO:0007264) 
44/439 7.04E-08 6.3E-05 
positive regulation of B cell activation 
(GO:0050871) 
12/58 3.79E-06 0.003 
regulation of Ras GTPase activity 
(GO:0032318) 
33/349 1.05E-05 0.005 
positive regulation of Ras GTPase 
activity (GO:0032320) 
29/292 1.42E-05 0.006 
muscle cell differentiation 
(GO:0042692) 
17/119 8.65E-06 0.005 
hemostasis (GO:0007599) 40/478 2.33E-05 0.008 
mitotic DNA damage checkpoint 
(GO:0044773) 
8/32 3.75E-05 0.0089 
Table 2.9: Top Gene Ontology Biological Process Terms Associated with Common 
Downregulated Genes.  Genes that are significantly downregulated at early time points post Mtb 
infection in all three macrophage states are analyzed through Web-based tool Enrichr. Here top 10 
most enriched GO biological process terms are shown in the table. 
Next, the unannotated tags, in other words, the tags that are not mapped to a gene by core 
FANTOM5 bioinformatics team, are investigated. Although there is a comparable number of 
annotated vs unannotated tags in mouse macrophages (Figure 2.3), there is more than one order of 
magnitude less differentially expressed unannotated tags compared to annotated tags shared by all 
three macrophage states (Figure 2.7). Additionally, the fold changes of the top upregulated and 
downregulated unannotated tags are dramatically lower compared to annotated tags since the range 
of TPM values of unannotated tags are dramatically smaller than annotated tags (Table 2.10). 
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When the genomic locations of these tags are scrutinized, there is no skew in frequencies between 
intergenic and intragenic locations (Table 2.11). Few of the tags show that they can be alternative 
transcription start sites for associated genes, a high possibility of transcription start site for mir339 
for a specific tag and the high possibility of transcription start site of enhancer RNA for another 
tag since it is located at bi-directional transcription initiation region.   
         Table 2.10: Top upregulated and downregulated unannotated tags common to different 
macrophage states. Fold change shown in the table corresponds to highest fold change in early 
time points (4h and 12h pi) when the TPM values are averaged over replicates. In the table, top 5 
common upregulated and downregulated unannotated tags are shown. 
 
 
 
 
 
 Non-stim 
macrophages 
IFNg-stim 
macrophages 
IL4IL13-stim 
macrophages 
Tag Position Fold 
Change 
p-value Fold 
Change 
p-value Fold 
Change 
p-value 
p@chr16:84703569,+ 112 9.8E-05 114 1.07E-04 149 1.07E-06 
 
p@chr2:136735887,+ 42.6 9.5E-04 27.5 1.2E-04 26.2 0.001 
p@chr1:58783008,+ 32.2 2.9E-04 28.3 1.1E-05 34.4 1.2E-04 
p@chr3:142224648,+ 32 1.3E-04 26.7 3.9E-05 33.8 0.002 
p@chr11:117839416,+ 20.1 6.4E-04 17.8 4.4E-05 17.9 0.003 
p@chr4:149942925,+ -12 2.9E-04 -12.2 4.6E-04 -15.4 0.002 
p@chr15:103164241,- -10.3 7.9E-11 -9.7 3E-04 -5.6 7.3E-05 
p@chr19:17401449,- -9.3 4.3E-04 -17.3 9.3E-04 -10.1 4.2E-04 
p@chr16:78217402,+ -8.9 0.001 -7.2 8.5E-05 -5.9 0.001 
p@chr5:139848167,- -8.6 7E-04 -8.6 1.9E-04 -10.7 7.7E-07 
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Tag Name Genomic Location 
p@chr16:84703569..84703586,+ Intergenic,10 kb upstream  of mir155 in an enhancer 
region 
p@chr2:136735887..136735907,+ Intragenic TSS in Slx4ip gene 
p@chr1:58783008..58783022,+ Intragenic TSS in Cflar gene (probably TSS for 
alternative isoform in Cflar) 
p@chr3:142224648..142224710,+ Intragenic TSS in Gbp3 gene (probably TSS for 
alternative isoform in Gbp3) 
p@chr11:117839416..117839490,+ Intergenic, 8.5 kb upstream of Pgs1 
p@chr4:149942925..149942944,+ Intragenic TSS in Rere gene 
p@chr15:103164241..103164267,- Intragenic TSS in Zfp385a gene 
p@chr19:17401449..17401453,- Intragenic TSS in Gcnt1 gene, at 3’ end of the 
transcript probably degradation product 
p@chr16:78217402..78217433,+ Intragenic TSS in predicted Gm2311 gene 
p@chr5:139848167..139848196,- Probable TSS for mir339 
  Table 2.11: Genomic locations of tags shown in Table 2.10. The genomic coordinates 
of the tags are provided as in mouse genome data mm9 assembly. 
 
5. DISCUSSION 
The work described in this chapter focused on the global transcriptomic and single RNA level 
responses of different macrophage polarization states to hypervirulent Beijing strain of Mtb. Single 
molecule CAGE Sequencing is employed that substantially increases the depth of sequencing. It 
is evident that nearly 45% of the significantly expressed (at least 10 TPM in at least one dataset of 
Mtb infection) CAGE tag clusters were not associated with TSS of a gene. An increasing amount 
of transcriptomics studies in Mtb infected macrophages have been published; however, they are 
not as vast as the present study in terms of macrophage polarization states and time kinetics [113, 
149-152]. The early response of M0 (non-polarized), M1 and M2 macrophages is more similar 
than expected, as both non-supervised hierarchical clustering and PCA analysis closely grouped 
same time points of different macrophage states instead of same macrophages states of different 
time points. While it may be somehow surprising, it shows that HN878 infection is such a strong 
perturbation of macrophage transcriptome, different polarization states respond in a similar fashion 
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in early time points. However; the response of M1 and M2 macrophages can be more sustained 
than M0 macrophages as it is seen in Figure 2.6. Another interesting fact is that M2 macrophages 
harbour more exclusive DE tags for both annotated and unannotated tags. It is more evident in 
unannotated tags since commonly DE tags account for 100 while M2 exclusive tags account for 
over 1000. The drastic increase in unannotated tags exclusively in M2 macrophages can be the 
result of alternative TSS in M2 macrophages since a higher proportion of unannotated tags are 
intragenic (Table 2.11). It has been shown that M1 and M2 activation of human macrophages can 
result in promoter switch and alternative TSS [153], although the authors report alternative TSS 
over 50 loci which is much less than expected. It is possible that Mtb infection can induce much 
higher promoter switch, since another level of RNA regulation, alternative splicing is shown to 
regulate transcriptional response to virulent and avirulent Mtb strains[154].   
When we look at the gene expression changes at the single transcript level, endothelin 1 is 
surprisingly among the highest upregulated transcripts in macrophages. Edn1 primarily functions 
as a vasoactive peptide involved in hypertension and various vascular diseases [155]. Blockage of 
Edn1 signaling leads to augmented lung lesions and infiltration of neutrophils in Mtb infected 
mice; however, the detailed mechanisms are not elucidated further [156]. It is possible that Edn1 
can stimulate the production of endothelial nitric oxide (eNOS) and in TB cavities which are 
generally characterized by a decrease in vascularization [157].  Highest upregulated transcripts 
include many genes that are studied in detail; such as prostaglandin synthase 2 is an enzyme that 
generates proinflammatory lipid signaling molecules, prostaglandins from arachidonic acid. 
Prostaglandins inhibit necrotic cell death in Mtb infected macrophages through plasma membrane 
repair processes to contain dissemination whereas competing lipid mediators, lipoxins mediate 
necrosis and facilitates immune evasion [158]. Interleukin-6 has distinct functions in tuberculosis 
pathogenesis; Il6 is shown to be crucial for protection when the mice are infected with high dose 
intravenously but dispensable in low dose aerosol Mtb infections [159, 160]. The release of Il-6 
by Mtb infected macrophages can inhibit IFNg responsive genes at the transcriptional level [161]; 
however, it is critical for generating protective IFNg positive Th1 cells after immunization with a 
subunit vaccine against Mtb [162]. Cxcl1, Cxcl2, and Cxcl3 are major chemoattractants for 
neutrophils and share a single receptor Cxcr2. Yet, these ELR+ chemokines have additive roles 
rather than redundant in neutrophil recruitment to the site of infection [163]. The more interesting 
transcripts are actually harbored in top downregulated DE transcripts since only Ccr2 is studied in 
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Mtb infection [164]. The presence of NFκB and MAPK signaling members in both kinase and 
transcription shows that these pathways are integral to response to Mtb infection in all polarization 
states. However; the presence of novel various signaling pathways and transcription factors 
provide new targets to elucidate the mechanisms of macrophage response and immune evasion 
strategies.  
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CHAPTER III 
BATF2: AN IMMUNE EVASION GENE IN VIVO 
 Classically activated macrophages are indispensable for the killing of Mtb, the release of 
proinflammatory cytokines and chemokines which in turn can drive adaptive immune response. 
M1 polarized macrophages are characterized by abundant expression of inducible nitric oxide 
synthase (iNOS) and production of nitric oxide (NO), production of proteolytic enzymes, the 
release of antimicrobial peptides, augmented phagocytosis and formation of the toxic intracellular 
environment [165]. Considering the hostile environment in M1 macrophages, it is intriguing to see 
that if transcription factors or molecular switches that govern M1 state can also take part in the 
killing of Mtb. Another facet of focusing on molecular mechanisms of M1 macrophages is to see 
whether prolonged M1 activation can be hindered by targeting M1 regulators in order to curtail 
destructive inflammatory responses. Accordingly, we concentrate on responses of M1 
macrophages to HN878 infection in our transcriptomics data. We analyzed the transcription factors 
which are highly upregulated after Mtb infection to understand their role mechanistically in the 
control of Mtb infection (Table 3.1). Top 20 upregulated TF-associated tags consist of mainly 
novel TFs that are not studied in Mtb infection before; except NF-κB family (Nfkbiz, Nfkbid, Rel, 
Nfkbib, and Nfkb1) which is a master transcription factor in bacterial infections. The comparison 
of our list with the TFs known to be involved in M1 polarization [166] revealed that only Maff, 
Zfp800 and Batf2 are common. Maff and Zfp800 are novel TFs for M1 polarization and Mtb 
response which are interesting to investigate further. However; we have recently published that 
Batf2 heterodimerizes with interferon regulatory factor 1 (Irf1) upon stimulation by IFNg and 
TLR2, TLR4 ligands and activates the expression of proinflammatory mediators; Nos2, Tnf, Ccl5 
and Il12b [167]. In a recent TB biomarker study, authors report that Batf2 signature alone is strong 
enough to distinguish pulmonary and extrapulmonary TB patients from healthy controls [168]. 
Hence, we seek to understand the role of Batf2 in Mtb infection both in vivo and in vitro. To our 
surprise, deletion of Batf2 renders the mice protected against H37Rv and HN878 Mtb strains. The 
manuscript presented below shows our collaborative work to elucidate the mechanism of action of 
Batf2 in Mtb infected mice and observational studies of human blood transcriptome. The PhD 
candidate performed validation experiments by RT-PCR from whole blood of healthy, latently 
infected and active TB individuals presented in Figure 1, RT-PCR experiments that shows 
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increased Batf2 expression in vivo following infection with Mtb presented in Figure 2 by himself; 
mortality experiments presented in Figure 3 and RT-PCR of various immune related genes from 
Mtb infected sorted cells presented in Figure 6 with Dr Reto Guler; immunohistochemistry, flow 
cytometry, bacterial burden and lung homogenate ELISA experiments presented in Figure 4 and 
Figure 5 with Dr Reto Guler and Dr Suraj Parihar; in vitro CFU assays and supernatant ELISA 
experiments presented in Figure 7 with Dr Suraj Parihar. 
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TF Cluster 
ID 
TF Protein Name Fold 
Change 
p-value 
p1@Maff Transcription factor MafF 213 1.6E-12 
p1@Nr4a1 Nuclear receptor subfamily 4 group A member 1 143 9.8E-08 
p2@Nfkbiz NF-kappa-B inhibitor zeta 98.7 7.5E-14 
p2@Nr4a3 Nuclear receptor subfamily 4 group A member 3 86.9 6.7E-08 
p1@Id3 DNA-binding protein inhibitor ID-3 80.8 1.6E-08 
p1@Egr1 Early growth response protein 1 77.3 1.4E-10 
p1@Mxd1 Max dimerization protein 1 67.1 1.8E-10 
p1@Hivep2 Transcription factor HIVEP2 59 5E-06 
p2@Nfkbid NF-kappa-B inhibitor delta 58.6 2.4E-06 
p1@Fosl1 Fos-related antigen 1 45.2 2.3E-07 
p5@Tgif1 Homeobox protein TGIF1 43.6 1.6E-06 
p1@Bhlhe40 Class E basic helix-loop-helix protein 40 43.3 3.7E-08 
p1@Zc3h12a Endoribonuclease ZC3H12A 30.5 1.3E-07 
p10@Zfp800 Zinc finger protein 800 28.6 8.4E-09 
p1@Id2 DNA-binding protein inhibitor ID-2 25 7.4E-07 
p2@Rel Proto-oncogene c-Rel 24.3 4.7E-07 
p2@Batf2 
Basic leucine zipper transcriptional factor 
ATF-like 2 
17.6 5.8E-06 
p2@Nfkbib NF-kappa-B inhibitor beta 14.2 1.1E-06 
p1@Nfkb1 Nuclear factor NF-kappa-B p105 subunit 11.8 3.5E-06 
p1@Ets2 Protein C-ets-2 11.5 5.3E-06 
Table 3.1: Top TF-associated tags in Mtb infected IFNg stimulated macrophages. A full 
list of mouse TFs are downloaded from TcoF-DB v2 [169] and all the transcripts associated with 
TFs are analyzed for differential expression. Highest upregulated 20 tags are shown in the table.  
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ABSTRACT  
We have previously shown that basic leucine zipper transcription factor (Batf2) regulates 
inflammatory responses in Mycobacterium tuberculosis (Mtb)-infected murine macrophages. 
Here, we show that BATF2 mRNA is highly expressed in peripheral blood from adolescents who 
progressed from infection to tuberculosis disease, and is a predictive human biomarker for incident 
tuberculosis disease. Subsequent infection studies with the clinical hypervirulent Mtb HN878 
strain in wild-type mice resulted in Batf2 up-regulation in lung macrophages, with increased 
proinflammatory responses and subsequent mortality. In contrast, Batf2-/- mice survived acute 
tuberculosis with reduced lung inflammation and histopathology compared to wild-type mice. This 
was due to reduced recruitment of inflammatory macrophages, diminished pro-inflammatory 
cytokines (Il1a, Il1b, Tnf) and immune effectors (Il12a and Nos2) in infected Batf2-/- lung 
macrophages. Conclusively, Batf2 increases tissue inflammation and tuberculosis 
immunopathology in mice. Hence, targeting BATF2 and its transcriptional pathway for possible 
adjunctive host-directed therapy may reduce pathological inflammation during Mtb infection.  
INTRODUCTION 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), causes 1.5 
million deaths per year globally [37]. Hence, there is a critical need to better understand host-
protective immunological responses, define more robust pre-clinical biomarkers for TB disease 
and subsequently develop more sensitive bioassays to detect Mtb early in the host [170, 171]. 
Identification of correlates of risk of TB will contribute to early intervention therapies to prevent 
TB disease. Previous transcriptomic studies in whole blood from participants living in TB endemic 
areas have identified unique transcriptional signatures distinguishing between active, latent, 
recurrent TB and uninfected individuals [115, 172-174]. These gene expression results were 
mapped to different functional pathways and revealed diverse modules including cytokines, 
chemokines, receptors, specific immune cells and inflammation markers. The identification of 
novel inflammatory biomarkers could be of particular interest since uncontained infection with 
Mtb in the host is accompanied by an inflammatory response contributing to the pathogenesis of 
the disease. Excessive inflammatory immune responses to Mtb infection results in tissue 
pathology, and if left untreated, can result in organ dysfunction and death. For example, excessive 
TNF production greatly contributes to the immunopathogenesis of TB disease by inducing necrosis 
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in Mtb-infected macrophages [55]. Therefore a protective therapy for TB should reduce 
inflammation, and adjunctive host-directed therapies for TB targeting inflammatory effectors may 
become biologically relevant to reduce TB pathogenesis [68, 175, 176]. It is imperative to identify 
novel inflammatory biomarkers, which are induced during the early stages of infection before 
developing active disease, as correlates of risk for TB.  
We previously identified Batf2 as a transcriptional inducer of inflammatory responses in 
Mtb-infected murine macrophages in vitro [167]. Recently, we identified BATF2 among a 16 
human gene signature of risk that predicted tuberculosis progression in adolescents [116]. With 
the goal of better understanding the biology behind TB disease progression, we searched for other 
transcription factors (TFs) among this gene set as potential master regulators of TB progression. 
Out of the 16 signature genes, three were TFs (BATF2, ETV7, and STAT1). The protective role 
of Stat1 during mycobacterial infection is well-defined [177], while the role of ETV7 and BATF2 
in TB disease progression is poorly defined. Unlike ETV7, BATF2 has a known mouse orthologue 
[178]. Moreover, a recent meta-analysis comparing 16 datasets among differentially expressed 
genes distinguishing active TB from controls, revealed a five gene signature that included BATF2 
[179].  
Batf2 is a transcription factor that belongs to the basic leucine zipper transcription factor 
family, which includes Batf and Batf3 family members [180, 181]. We previously reported that 
Batf2 associates with Irf1 to induce inflammatory responses in IFN-γ and LPS-activated 
macrophages [167]. Knockdown of Batf2 by shRNA in IFN-γ or LPS-activated macrophages 
caused significant reduction of important early immune response genes (Tnf, Ccl5, and IL12b) 
including the bacterial effector killing gene Nos2. In this study, using human whole blood 
transcriptomics, we identified elevated expression of BATF2 as an early correlate for TB disease 
progression in adolescents with latent Mtb infection. We further explored the role of Batf2 in a 
loss of function approach using Mtb-infected Batf2 deficient mice in comparison to infected wild-
type mice. Interestingly, Batf2-/- mice were highly resistant to tuberculosis disease exhibiting 
reduced tissue inflammation, pulmonary histopathology, and subsequently increased survival 
during acute infection. Mechanistically, we identified Batf2 as a transcriptional inducer of 
inflammatory responses during Mtb infection in mice and showed that BATF2 is a predictive 
biomarker for TB disease in humans in a prospective cohort study in adolescents.  
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RESULTS  
Increased BATF2 gene expression correlates with human TB disease progression  
Recently, we identified a TB risk signature profile of 16 human genes (Fig. 1a) in whole 
blood that differentiated infected adolescents who progressed to TB disease from adolescents who 
remained healthy [116]. Among these 16 genes, three transcription factors, BATF2, ETV7, and 
STAT1, significantly increased during progression from latent Mtb infection to TB disease (Fig. 
1b). The difference in expression became more pronounced during progression, but significant 
upregulation in progressors, relative to non-progressor controls, was detected approximately 600 
days before TB was diagnosed. Little information is available on the functional role of BATF2 in 
TB disease progression. Thus we focused on BATF family members and showed that BATF2 gene 
expression is highly induced during human TB disease progression. By contrast, BATF and 
BATF3 expression levels were not increased (Fig. 1c). We previously showed that BATF2 
associated with IRF1 to induce inflammatory responses in macrophages [167]. Here we show that 
IRF1 was also significantly upregulated during TB disease progression, similarly to BATF2 (Fig. 
1c). Validation experiments by RT- PCR confirmed that BATF2 expression was significantly 
increased (5-fold) in participants with active TB disease when compared to healthy controls (both 
QFT- and QFT+). Together, these data suggest that elevated BATF2 expression is a good indicator 
of host transcriptional inflammation that characterizes TB disease progression.  
Increased Batf2 mRNA expression in murine lung macrophages following infection with Mtb  
In a genome-wide transcriptomics analysis, we previously reported that Batf2 is induced 
in Mtb-infected and IFN-γ activated macrophages in vitro [167]. To evaluate Batf2 gene 
expression in an experimental TB disease model in vivo, Batf2 mRNA expression was determined 
in CD11bmedCD11clow FACS-sorted lung macrophages from Mtb-infected mice. Batf2 mRNA 
expression was significantly induced in wild-type lung macrophages at 3 weeks post infection with 
the laboratory strain H37Rv (Fig. 2a), as well as 11 and 21 days, post infection with the clinical 
hypervirulent Beijing Mtb strain HN878 (Fig. 2b). As expected Mtb-infected Batf2 deficient 
(Batf2-/-) mice did not express Batf2 mRNA in lung macrophages. Taken together, these data 
show that Batf2 is highly upregulated in lung macrophages during acute Mtb infection.  
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Batf2-/- mice are resistant to the hypervirulent HN878 strain of Mtb  
To explore the in vivo consequence of Batf2 deficiency in Mtb infection, a lethal dose of 
hypervirulent Mtb HN878 (350 CFU/mouse) was intranasally administered to Batf2-/- mice, 
heterozygous littermates (Batf2+/-) and control littermates (WT). Early weight loss (Fig. 3a) and 
subsequent mortality (Fig. 3b) was observed in control littermates, whereas no evident weight loss 
was observed in Batf2-/- and Batf2+/- mice. Strikingly, 71.4% of the control littermates and 40% 
of the heterozygous mice died during the experiment, whereas all infected Batf2-/- mice survived 
18 weeks post infection, at the time point where the experiment was terminated. Kaplan-Meier 
analysis demonstrated significant survival differences (P = 0.0015) between WT and Batf2-/- but 
also significant survival differences (P = 0.029) between heterozygous Batf2+/- and Batf2-/-, 
revealing a gene dose effect. Of interest, control mice started to die early at 4 weeks post infection 
with high pulmonary bacterial burden from 1-2x109 CFU. Infected heterozygous Batf2+/- mice 
died between 7 and 18 weeks with 2-70x105 CFU. The remaining Batf2-/- mice at the termination 
of the experiment had pulmonary bacterial burden from 2-20x105 CFU. Early during infection at 
11 days post HN878 inoculation, Batf2-/- had significantly reduced lung burden when compared 
to WT and Batf2+/- mice (Fig. 2c). Together, this demonstrates that absence of Batf2 in mice 
reduces early bacterial burden and increases resistance to acute and chronic Mtb infection, 
suggesting that Batf2 may be detrimental in tuberculosis disease.  
Mtb-infected Batf2-/- mice show reduced acute lung inflammation  
To further analyze the role of Batf2 in TB, a sublethal dose (100 CFU/mouse) of Mtb 
HN878 was used. Batf2 deficient and heterozygous mice showed a tendency for reduced  bacterial 
burden in the lung at week 3 and 6 post infection, compared to wild-type controls,  (Fig. 4a), with 
slightly reduced lung weight index (Fig. 4b), pulmonary cell infiltration (Fig.  4c) and iNOS 
expression (Fig. 4d) compared to WT littermate controls. However, lesion size (Fig. 4e), 
histological score (Fig. 4f) and histopathology of lungs (Fig. 4g) at week 3 were significantly 
reduced in Batf2-/- and Batf2+/- mice compared to infected WT littermate controls. These results 
suggest that the presence of Batf2 during sub-lethal infection does not significantly influence early 
bacterial burden but strikingly increases histopathology due to increased pulmonary inflammation 
and lesion size.  
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Batf2 increases lung TNF levels and cellular lung infiltration of inflammatory macrophages  
To better define cellular infiltration in the lungs we analyzed lung cell populations by flow 
cytometry, 3 weeks post infection with 1000 CFU/mouse of Mtb H37Rv. Although CFU counts 
were similar between WT and Batf2-/- mice (Fig. 5a), Mtb infection resulted in slightly lower total 
lung weight and significantly reduced lung cell numbers in Batf2-/- mice compared to WT mice 
(Fig. 5b and 5c). In particular, the percentage and total cell numbers of recruited 
CD11bmedCD11clow inflammatory macrophages were significantly lower in Batf2-/- mice (Fig. 5d, 
e). Cell numbers but not the percentages of CD11blowCD11chigh alveolar macrophages were 
significantly reduced in Batf2-/- mice. TNF, an important pro-inflammatory cytokine mainly 
produced by activated macrophages in the lungs during Mtb infection, was significantly reduced 
in Batf2-/- mice when compared to WT mice (Fig. 5f). Together, these data suggest that the 
presence of Batf2 leads to increased inflammation, demonstrated by enhanced TNF production 
and increased recruitment of inflammatory macrophages at the site of pulmonary infection.  
Batf2 induces pro-inflammatory responses in lung macrophages following Mtb infection  
To examine the consequence of Batf2 deletion on inflammatory responses in lung 
macrophages, mRNA expression of various inflammatory effectors was measured by RT- PCR in 
CD11bmedCD11clow inflammatory lung macrophages isolated from mice infected with Mtb H37Rv 
for 3 weeks (Fig. 6). Batf2 deficient lung macrophages had significantly reduced transcription of 
several pro-inflammatory cytokines, such as Il1a, Il1b, Tnf, and Il12a. Moreover, Nos2, the 
enzyme producing the anti-mycobacterial effector molecule NO, was significantly reduced in 
Batf2-/- compared to WT lung macrophages. In the absence of Batf2, Il10, an anti-inflammatory 
cytokine along with a suppressor for cytokine signaling (Socs1) was also significantly reduced. 
We previously reported that Batf2 associates with Irf1 to induce inflammatory macrophage 
responses [167]. Here we show that Irf1 is also significantly reduced in the absence of Batf2 in 
lung macrophages. Together, these results suggest that Batf2 is important in the regulation of 
inflammatory responses in lung macrophages following Mtb infection.  
Batf2 induced TNF and NO production in bone marrow-derived macrophages (BMDM)  
We previously reported in BMDM that Batf2 is essential for IFN-γ and LPS-induced Nos2 
and Tnf expression by using shRNA mediated Batf2 knockdown [167]. Here we extend these data 
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and show that Batf2 deficient BMDM stimulated with IFN-γ and IFN-γ/LPS produce significantly 
reduced levels of TNF following H37Rv Mtb infection compared to WT BMDM (Fig. 7a). In the 
absence of Batf2, TNF levels were also significantly reduced in IFNγ-stimulated Batf2-/- BMDM 
following infection with the HN878 strain of Mtb (Fig. 7b). Nitrite levels were significantly 
reduced in IFN-γ/LPS stimulated BMDM following H37Rv infection and in IFNγ-stimulated 
BMDM following HN878 infection. Together, these results show that Batf2 induces TNF and NO 
production in BMDM following in vitro infection with Mtb, suggesting that Batf2 directly 
regulates macrophages in vivo.  
DISCUSSION  
In this study, we demonstrated that the basic leucine zipper transcription factor (Batf2), 
which we [167] and others [182] recently identified in IFN-γ activated classical macrophages, was 
induced during Mtb infection in macrophages. Subsequent in vivo loss of function studies, 
comparing Mtb-infection of Batf2 deficient mice and wild-type mice, demonstrated that Batf2 
induced inflammatory macrophages to produce pro-inflammatory cytokines in the lung. This 
response resulted in early pulmonary inflammation and subsequent mortality post Mtb- infection 
in wild-type mice compared to Batf2 deficient mice. Hence, this demonstrated that Mtb-induced 
Batf2 expression is detrimental in pulmonary murine tuberculosis. This is also of relevance for 
human TB as we, in a recent South African adolescent cohort study [116], identified increased 
BATF2 expression by RNA sequencing in whole blood of asymptomatic individuals who progress 
to active TB disease (Fig. 1). This matches our mouse studies and conclusions and implies that 
BATF2 can be used as an urgently needed predictive marker for disease progression in populations 
living in TB endemic areas 
Batf2 is a basic leucine zipper transcription factor of the Batf family, with various immune 
regulatory functions [180]. Little is known about the functional role of the Batf family in TB 
disease development. Previously it was reported that Batf3 deficient mice had similar survival 
rates to Mtb infection compared to wild-type mice [182]. We recently reported that Batf2 is 
essential in macrophage activation and showed that lentivirus-mediated knockdown of Batf2 
resulted in reduced inflammatory macrophage responses during stimulation with LPS, IFN-γ or 
heat-killed Mtb [167]. This suggests that upon cell stimulation the presence of Batf2 
transcriptionally polarizes macrophages towards an inflammatory activation status. Mtb induces 
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pro-inflammatory responses in the host and the presence of BATF2 in individuals developing 
progressive pulmonary TB (Fig. 1) could be an indication of an increased inflammatory response 
in active TB disease patients. Indeed, we showed that Batf2 expression in lung macrophages 
progressively increased during Mtb infection in mice inoculated with the hypervirulent HN878 
strain of Mtb, a clinical isolate known to induce inflammation in the host [183, 184]. BATF2, also 
known as SARI, was also detected in human lung tissue but interestingly its expression decreased 
during clinical stage of lung cancer [185]. Upon infection with the HN878 strain of Mtb that 
induces a hyper-inflamed immune response in rabbits [183], we showed that Batf2 deficiency in 
mice resulted in survival when compared to control mice that succumbed to infection. Survival 
correlated with reduced pulmonary inflammation. The observed lung granulomas were reduced 
but more compact, and the lungs maintained the bacillary load as shown by similar CFU counts 
among the groups. Uncontrolled excessive lung pathology can lead to TB disease progression. Ill-
defined granuloma formation and uncontrolled pulmonary lesion sizes can lead to an aggressive 
TB pathology, tissue damage, and death. Infecting mice with a high inoculum dose of Mtb H37Rv 
resulted in significantly diminished lung inflammatory macrophages and decreased lung TNF 
levels in Batf2 deficient mice. However, infected Batf2-/- mice were still able to control the 
bacillary loads. Although TNF is important for inducing protective immune responses against Mtb 
infection [186], TNF was also reported to mediate TB pathogenesis [55]. Therefore, the 
inflammatory response observed during Mtb infection needs to be balanced and an over-inflamed 
state of immune activation may lead to TB disease and tissue pathology. For example, this balance 
between pro- and anti-inflammatory signals can be observed spatially within lung granulomas 
during Mtb infection [187]. In our study, we show that blocking Batf2 could dampen this over-
inflamed state and lead to resistance to Mtb infection. We demonstrated that Batf2 exerts its action 
in lung macrophages, as isolated pulmonary Batf2-/- macrophages during Mtb infection had a 
significantly reduced pro-inflammatory chemokine and cytokine response when compared to 
macrophages from wild-type mice (Fig. 6). The increased resistance of Batf2-/- to Mtb infection 
is similar to mice lacking the receptor for type 1 IFN [188]. For example, the absence of IFNar1 
in mice resulted in reduced early lung inflammation with smaller pulmonary inflammatory foci. 
Similar to our results in Batf2 deficient mice, IFNar1-/- mice displayed a reduced recruitment of 
inflammatory macrophages with decreased lung chemokines, pro-inflammatory cytokines such as 
Il1a, IL1b, Tnf, Il6 and decreased nitric oxide killing effector function. Although the lung bacterial 
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burden reached a level close to 105 CFUs, IFNar1-/- mice were highly resistant to Mtb infection. 
The mechanisms of increased resistance of Batf2-/- mice could be explained by reduced 
recruitment of inflammatory macrophages to the site of infection. It seems that Mtb intensifies 
inflammation to develop a persistence replication niche in the host. As TB disease progresses, the 
accumulation of inflammatory cells drives lung tissue pathology and allows for a permissive state 
where Mtb can replicate. Indeed, granulocyte depletion significantly extended the survival of Mtb-
infected mice [189] and TB susceptibility is determined by increased accumulation of a permissive 
monocyte/macrophage population in the lung [190].  
Taken together, our results implicate BATF2 as a possible key transcription factor that 
regulates the inflammation that characterizes progression from infection to TB disease and as a 
potential adjunctive host-directed drug target against TB. In a scenario where Mtb infection leads 
to excessive lung pathology, blocking BATF2 could reduce inflammation, limit pulmonary 
pathology and subsequently ameliorate TB disease outcome.  
METHODS  
Mouse strains  
Batf2 deficient mice (Batf2-/-) were generated in 129S6/SvEvTac-derived EDJ22 
embryonic  stem cells [182] and heterozygous mice (Batf2+/-) were purchased from Jackson 
Laboratories (600  Main Street Bar Harbor, Maine 04609 USA), subsequently intercrossed to 
generate Batf2-/-, Batf2+/- and littermate control Batf2+/+ 129S6/SvEv mice at the Animal 
Research Facility, University of Cape Town, Cape Town, South Africa.  
Ethics Statement  
All animal experiments were performed in accordance with the South African National 
Standard (SANS 10386:2008) and University of Cape Town of practice for laboratory animal 
procedures. The protocol (Permit Number: 012/036) was approved by the Animal Ethics 
Committee, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. The 
human adolescent cohort study (Permit Number: 045/2005) was approved by the Human  Ethics 
Committee, Faculty of Health Sciences, University of Cape Town, Cape Town.  
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Mtb infection in mice  
Anesthetized mice were infected intranasally by inoculation with 25 μl of viable HN878 
or H37Rv Mtb bacilli into both nasal cavities. Inoculum dose was determined at one day post 
infection. Bacterial loads, histopathological and flow cytometry analyses in lungs of Mtb-infected 
mice were determined as previously described [191].  
BMDM generation and in vitro Mtb infection  
Bone marrow-derived macrophages were generated from 8-12 week old wild-type and 
Batf2 deficient male mice as described previously [167]. After differentiation, BMDM were plated 
into 96-well plates (Nunc, Denmark) at 2 x 105 cells per well. Following overnight adherence, 
macrophages were stimulated with IFN-γ (100 U/ml, BD Biosciences, San Jose, CA), a 
combination of IFN-γ + LPS (20 ng/ml, Sigma Aldrich) or left unstimulated overnight. Activated 
BMDM were then infected with Mtb HN878 or H37Rv (MOI=5) for 4 hours. BMDM were washed 
once with pre-warmed culture media to remove extracellular bacteria and incubated with media 
containing fresh activators and 50 μg/ml of gentamycin. At 4 days post infection, the supernatant 
was collected to measure Tnf and NO2- levels.  
Quantitative real-time RT-PCR  
Total RNA (30 ng from each sorted murine cell populations) was reverse transcribed by 
Transcriptor First Strand cDNA Synthesis Kit (Roche) by using both random hexamer primer and 
anchored oligo dT primers according to manufacturer's instructions. Real-time PCR was 
performed with LightCycler® 480 SYBR Green I Master mix in LightCycler® 480 II (Roche). 
Absolute quantification method for each gene was used and normalized to Hprt. From the human 
adolescent cohort study [192], RNA was extracted from whole blood from healthy QFT- (n=16), 
healthy QFT- (n=16) and TB disease progressors (n=8). Here 100 ng of total RNA was extracted 
from PAXgene tubes and cDNA synthesis was performed with SuperScript II Reverse 
Transcriptase (Life Technologies). Real time PCR was performed as described for murine cell 
populations.  
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Measurement of nitric oxide and TNF in culture supernatants  
BMDM culture supernatants were analyzed for the production of NO2- using the Griess 
reagent assay and TNF by standard sandwich ELISA using PNP (4-nitrophenyl disodium salt- 
hexahydrate) substrate solution (Sigma Aldrich).  
The Adolescent Cohort Study  
To examine gene expression during human progression from Mtb infection to TB disease, 
we analyzed whole blood gene expression data from a prospective epidemiological cohort study 
in adolescents with latent Mtb infection and TB disease, aged 12-18 years, from the Western Cape 
of South Africa [192]. 6,363 high school adolescents were recruited and monitored for 2 years for 
the development of TB disease. Latent Mtb infection was diagnosed by tuberculin skin test or 
QuantiFERON Gold TB in Tube assay and whole blood was collected in PAXgene tubes at 
enrollment and end of study (24 months) in all, and in an active follow-up group also at 6, 12 and 
18 months [116]. Participants suspected of having either prevalent or incident TB were 
investigated through sputum smears, culture, and chest X-ray. A protocol- defined incident case 
of TB was any case confirmed by two or more sputum smears positive for acid-fast bacilli and/or 
one positive sputum culture for M. tuberculosis [116]. Non-progressor controls were matched to 
progressors by age, gender, ethnicity, high school and previous history of TB disease.  
RNA-Seq  
RNA-Seq was performed on whole blood samples from 46 progressors and 107 non-
progressor controls as previously described [116]. Briefly, RNA was extracted and globin 
transcript depletion (GlobinClear, Life Technologies) was followed by cDNA library preparation 
using Illumina mRNA-Seq Sample Prep Kit. RNA-Seq was performed by Expression Analysis 
Inc., at 30 million 50bp paired-end reads, on Illumina HiSeq-2000 sequencers. Read pairs were 
aligned to the hg19 human genome using gsnap [193]. Mapped read pairs were assigned to genes 
by collapsing all transcripts into a single gene model and counting the number of reads that fully 
overlap the resulting exons using htseq (v. 0.6.0) [194] with strict intersection and including strand 
information. Gene models for protein-coding genes were downloaded from Ensembl 
(GRCh37.74). Reads that mapped to multiple locations were only counted once and those mapping 
to ambiguous regions were excluded. Log2-transformed values of counts normalized by adjusted 
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library counts were computed using the cpm function of the edgeR package [195]. Gene-level log2 
fold changes comparing each  TB progressor sample to the average of demographically matched 
healthy control samples were computed using the Adolescent Cohort Study metadata [116], and 
assigning “days before  TB disease” values for each sample according to the original definitions. 
The gene expression fold changes for all TB progressor samples were modeled as a nonlinear 
function of “days before TB disease” for the entire population using the smoothing spline function 
in R with three degrees of freedom. Ninety-nine percent confidence intervals for the temporal 
trends were computed by performing 2000 iterations of spline fitting after bootstrap resampling 
from the full dataset.  
Statistical analysis 
All data were analyzed using GraphPad Prism v 6.0, a student t-test (two-tailed with 
unequal variance) or unless otherwise stated in figure legends. A ‘p’ value of less than 0.05 was 
considered significant. 
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Figure 1. Increased Batf2 expression in human whole blood as a correlate for TB risk 
progression. (a) Whole blood RNA sequencing and qRT-PCR was employed to define risk 
signature profiles of 16 genes to predict TB progression that contains three transcription factors, 
adapted from [116]. (b) ETV7, STAT1 (c) BATF, BATF2, BATF3 family members and IRF1 
expression was determined by RNA sequencing in TB progressors in comparison to healthy non-
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progressor participants and plotted as log2 fold changes (FC) versus days before TB disease. The 
dotted line represents spline fit to the overall dataset, and the shaded blue areas represent 99% 
bootstrap confidence intervals for the spline fits to the fold change of gene expression, as 
determined by RNA-Seq, in TB progressors vs. healthy non-progressor controls. (d) BATF, 
BATF2, BATF3 and IRF1 mRNA expression relative to HPRT1 housekeeping gene was 
determined by RT-PCR from whole blood of healthy, QuantiFERON Gold TB In-Tube negative 
(QFT-) and positive (QFT+) adolescents, and participants diagnosed with active tuberculosis (TB) 
disease (One-way ANOVA with Tukey’s multiple comparison tests). 
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Figure 2. Enhanced Batf2 mRNA expression in murine lung macrophages during acute Mtb 
infection. Control littermates (WT) and Batf2-/- mice were infected intranasally with (a) 1000 
CFU/mouse of H37Rv Mtb (n=5 mice/group) and (b) 350 CFU/mouse of HN878 Mtb (n=5 
mice/group). Mice were sacrificed at (a) 21 days and (b) 11 and 21 days post infection to sort 
CD11bmedCD11clow lung macrophages by flow cytometry. Batf2 mRNA expression relative to 
Hprt housekeeping gene was determined by RT-PCR in isolated macrophages (N.D. = not 
detected). 
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Figure 3. Batf2 deletion renders mice resistant to hypervirulent Mtb HN878 infection. 
Control littermates (WT), heterozygous littermates (Batf2+/-) and Batf2-/- mice were infected 
intranasally with 350 CFU/mouse of Mtb HN878 (n=7-10 mice/group). (a) Body weight change 
in percentages and (b) survival of infected mice are shown with indicated CFU/lung from 
moribund mice and mice that were sacrificed at the termination of the experiment. Kaplan-Meier 
survival analysis with log rank test P = 0.0015, WT vs. Batf2-/- and P = 0.029, Batf2+/- vs. Batf2-/- 
(c) Lung bacterial burden was determined at 11 days post infection  following infection with 350 
CFU/mouse of Mtb HN878 (n=3-5 mice/group). Data shown in a and b are representative of three 
independent experiments (* P < 0.05). 
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Figure 4. Reduced lung inflammation in Batf2 deficient mice during acute Mtb HN878 
infection. Control littermates (WT), heterozygous littermates (Batf2+/-) and Batf2-/- mice were 
infected intranasally with 100 CFU/mouse of hypervirulent Mtb HN878 (n=10 mice/group). Mice 
were sacrificed at 3 and 6 weeks post infection to determine (a) bacterial burden, (b) lung weight 
index and (c) lung cell numbers. Pulmonary histopathology was determined at 3 and 6 weeks post 
infection with H&E, iNOS, and Ziehl-Neelsen (ZN) staining. (d) iNOS staining (brown color) per 
lung section quantified as area in μm2. (e) Total H&E lesion size was quantified from ten deep cut 
lung sections (30 μm apart). (f) Lung histopathology scores graded from 1-10 based on 
perivascular/ peribronchiolar lymphocytic infiltrates, reduced ventilated alveolar spaces and 
extensive pulmonary lesions (** P < 0.01). (g) Representative histopathology sections at 3 weeks 
post infection for H&E, iNOS (scale bar = 50 μm) and ZN (scale bar = 5 μm). 
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Figure 5. Reduced inflammatory macrophages in Batf2-/- lungs following infection with the 
Mtb strain H37Rv. Control littermates (WT) and Batf2-/- mice were infected intranasally with 
1000 CFU/mouse of H37Rv Mtb (n=4-5 mice/group). Mice were sacrificed at 3 weeks post 
infection to determine (a) CFU loads in the lungs, (b) lung weight and (c) lung cell numbers. (d- 
e) The percentage and total number of alveolar macrophages (CD11blowCD11chigh) and recruited 
inflammatory macrophages (CD11bmedCD11clow) were determined by flow cytometry. TNF levels 
in lung homogenates were determined by ELISA (* P < 0.05, ** P < 0.01). 
 
 
 
 
77 
 
 
Figure 6. Reduced expression of pro-inflammatory mRNA in isolated lung Batf2-/- 
macrophages following infection with H37Rv at 3 weeks post infection. Control littermates 
(WT) and Batf2-/- mice were infected intranasally with 1000 CFU/mouse of H37Rv Mtb (n=5 
mice/group). Mice were sacrificed at 3 weeks post infection to sort CD11bmedCD11clow 
inflammatory lung macrophages in the lungs by flow cytometry. mRNA expression was 
determined by RT-PCR in sorted cells from naïve and 3 weeks Mtb-infected mice (* P < 0.05, ** 
P < 0.01, *** P < 0.001; N.D. = not detected). 
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Figure 7. Reduced TNF and NO production in classically activated Batf2-/- macrophages 
following Mtb infection. Control littermates (WT) and Batf2-/- BMDM were stimulated with  
IFN-γ (100 Units/ml), a combination of LPS (20ng/ml) + IFN-γ (100 Units/ml) or left unstimulated 
overnight followed by infection with either (a) H37Rv or (b) HN878 strain of  Mtb. Supernatants 
were collected at 4 days post infection to measure TNF and NO2- levels  (* P < 0.05, ** P < 0.01). 
 
 
 
 
 
 
 
79 
 
CHAPTER IV 
PRKCD: A HOST PROTECTIVE GENE IN VIVO  
 Alternatively activated macrophages play a role in various tasks including dampening 
inflammation, tissue remodeling and wound repair and parasite killing. Best action of play for Mtb 
to evade classically activated macrophage killing is to shift them towards alternative phenotype. 
Increased levels of M2 activation correlates with susceptibility to TB [149, 196] and type 2 
environment can change back towards type 1 environment after successful anti-TB treatment 
[197]. Similarly, IFNg mediated type 1 response dominates first three weeks in Mtb infected mice, 
later shifted towards type 2 immune response with high IL-4 levels [198].  Type 2 response 
polarized macrophages towards M2 phenotype which is immunomodulatory and have poor 
bacterial killing capabilities [199]. Additionally, they harbor less nitric oxide and higher 
availability of iron that results in a permissive niche inside macrophages [149]. M1 macrophages 
retain iron in the cytosol, away from phagosomal compartments which result in bacteriostasis of 
Mtb [200], hence it is interesting to see whether Mtb manipulates host transcriptome to induce M2 
associated pathways. For this reason, we ask to find kinase associated tags that are upregulated in 
M2 macrophages after Mtb infection however not liberally upregulated in M1 macrophages (Table 
4.1). We choose kinases to focus on since they take crucial roles extensively to regulate complex 
processes and they are easier to target for future intervention approaches. This approach yielded 
only two kinases TSSs out of top 10 upregulated TSSs in M2 macrophages. Protein kinase, cGMP-
dependent, type I (Prkg1) is a novel kinase to study since it is studied neither in M2 macrophages 
nor in responses to Mtb infection. We select protein kinase C delta (Prkcd) to further pursue our 
studies in order to understand extensively its role during Mtb infection. Prkcd has actually been 
studied in our lab with different infectious disease models. Mice deficient with PKCδ is highly 
susceptible to Listeria monocytogenes infection because of the increased escape of the pathogen 
from phagosomes into the cytosol, hence increased bacterial burden [201]. PKCδ deficient mice 
are also shown to be more susceptible to Leishmania major infection since PKCδ deficient 
macrophages and DCs are unable to produce sufficient levels of IL12p40/p70 which results in less 
efficient T cell priming [202]. The manuscript presented below shows our collaborative work to 
elucidate the mechanism of action of PKCδ in Mtb infected mice and observational studies of 
human blood transcriptome and lung proteome. The PhD candidate performed qRT-PCR analysis 
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of PKCδ in human blood and Mtb-infected human macrophages presented in Figure 1 by himself, 
mortality study and in vivo bacterial burden studies presented in Figure 2 and 3, lung homogenate 
ELISA and FACS analysis presented in Figure 4, in vitro mycobacterial growth and killing effector 
function assays presented in Figure 6 and 7 with the lead author Dr. Suraj Parihar. 
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Kinase 
Cluster ID 
Kinase Protein Name  M2 Fold 
Change 
p-value M1 Fold 
Change 
p-value 
p1@Rps6ka2 Ribosomal protein S6 kinase 
alpha-2 
55.2 1.1E-07 26.4 1.2E-04 
 p2@Mapk6 Mitogen-activated protein kinase 
6 
39.4 1.7E-06 47.5 8E-06 
p1@Met Hepatocyte growth factor receptor 33.6 2.3E-08 15.8 3.8E-06 
p1@Plk2 Serine/threonine-protein kinase 
PLK2 
30.1 4.3E-07 58.8 1.8E-07 
p1@Plk3 Serine/threonine-protein kinase 
PLK3 
18.8 1.2E-05 20.8 8.2E-07 
p1@Ripk2 Receptor-interacting 
serine/threonine-protein kinase 2 
18.8 9.2E-07 23.2 1.7E-06 
p2@Rps6ka3 Ribosomal protein S6 kinase 
alpha-3 
11.8 6.5E-05 24.5 2.1E-04 
p4@Irak3 Interleukin-1 receptor-associated 
kinase 3 
11.2 3E-04 3.8 7.5E-06 
p1@Jak2 Tyrosine-protein kinase JAK2 7.5 1.9E-04 5 0.002 
p2@Prkg1 cGMP-dependent protein kinase 1 6.7 6.4E-04 1.8 >0.05 
p3@Prkcd Protein kinase C delta type 4 3.9E-03 0.3 >0.05 
Table 4.1: Top kinase associated tags in Mtb infected IL4/IL13 stimulated macrophages 
Full list of mouse kinome is downloaded from UniProt (Release: 15 Feb 2017) and all the 
transcripts associated with kinases are analyzed for differential expression. Highest 
upregulated 10 tags for Mtb infected M2 macrophages are chosen and shown with their FC in 
M1 macrophages in the table. 
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PROTEIN KINASE C-DELTA (PKCD), A MARKER OF INFLAMMATION AND 
TUBERCULOSIS DISEASE PROGRESSION IN HUMANS, IS IMPORTANT FOR 
OPTIMAL MACROPHAGE KILLING EFFECTOR FUNCTIONS AND SURVIVAL IN 
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ABSTRACT 
We previously demonstrated that Protein Kinase C-delta (PKC-δ) is critical for immunity 
against Listeria monocytogenes, Leishmania major, and Candida albicans infection in mice. 
However, the functional relevance of PKCδ during Mycobacterium tuberculosis (Mtb) infection is 
unknown. PKCδ was significantly upregulated in patients with active TB disease and lung 
proteomics further revealed that PKCδ was highly abundant in the necrotic and cavitory regions 
of TB granulomas in multi-drug resistant human participants. In murine Mtb infection studies, 
PKCδ-/- mice were highly susceptible to tuberculosis with increased mortality, weight loss, 
exacerbated lung pathology reflected by uncontrolled pro-inflammatory cytokine responses and 
increased mycobacterial burdens. Moreover, these mice displayed a significant reduction in 
alveolar macrophages and dendritic cells, reduced accumulation of lipid bodies (in lungs and 
macrophages) and serum fatty acids. Further, a peptide inhibitor of PKCδ in wild-type mice caused 
increased inflammation in the lungs similar to PKCδ-/- mice. Mechanistically, increased bacterial 
growth in macrophages from PKCδ-/- mice was associated with a decline in killing effector 
functions independent of phagosome maturation and autophagy. Taken together, these data suggest 
that PKCδ is a marker of inflammation during active TB disease in humans and required for 
optimal macrophage killing effector functions and host protection during Mtb infection in mice. 
INTRODUCTION 
Protein Kinase C-delta (PKCδ) plays a multitude of physiological roles through its ability 
to phosphorylate multiple target proteins involved in various cellular processes such as signal 
transduction [203], apoptosis [204], proliferation and survival [205], transcription [206], hormonal 
regulation [207] and immune responses [201, 202]. PKCδ-/- mice were originally characterized by 
two independent research groups, who highlighted the role of this kinase in B cell anergy [208] 
and B cell-mediated autoimmunity [209]. Furthermore, PKCδ-/- mice were protected against high-
fat-diet-induced glucose intolerance by exhibiting reduced accumulation of liver triacylglycerol 
and impaired production of lipogenic enzymes [210].  
Most studies on the role of PKCδ were performed using inhibitors in vitro, which lacked 
in specificity to a particular PKC isoform. A frequently used example is rottlerin, which is a non-
specific inhibitor of PKCδ to block enzymatic reactions and intracellular signaling in pancreatic 
acinar cells [211]. Rottlerin was shown to reduce viral burdens in human monocyte-derived 
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macrophages during the early stages of HIV-1 infection [212]. Physiologically, inhibition of 
PKCδ, with either rottlerin or anti-PKCδ siRNA, resulted in increased cholesterol efflux in hamster 
kidney cells and a murine macrophage cell line RAW264.7 [213]. Moreover, PKC isoforms such 
as δ and , are required for phagocytosis in RAW264.7 macrophages [214], and PKC also 
regulates the autocrine production of TNF, which in turn induces apoptosis in LPS-activated 
macrophages [215]. 
Studies have suggested a functional role for PKCδ in regulating immunity to infectious 
diseases in vivo. Previously, using PKCδ-/- mice, we demonstrated a crucial role of this kinase in 
macrophage-mediated phagosomal clearance of the intracellular bacterium, Listeria 
monocytogenes [201]. We further reported that PKCδ regulates the production of IL-12p40/70 in 
both macrophages and dendritic cells, required for protective Th1 immune responses in a murine 
model of cutaneous leishmaniasis [202]. We also demonstrated that deletion of PKCδ renders mice 
susceptible to Candida albicans infection via Card9-mediated anti-fungal immunity [216]. These 
studies highlighted the key role of PKCδ in the immune response to infectious diseases. However, 
the functional significance of this PKCδ in tuberculosis infection has not been studied yet. 
Here, we investigate the role of PKCδ in host immunity to Mtb in human participants and 
in a murine model of tuberculosis. We report that PKCδ mRNA expression is increased in 
peripheral blood of participants with active tuberculosis. Additionally, proteomic analysis of lung 
tissues from treatment-refractory tuberculosis patients reveals higher levels of PKCδ protein 
expression in caseous and necrotic regions of cavitory granulomas, highlighting that PKCδ might 
be an indicator of an inflammation. We further demonstrate that deletion of PKCδ in mice has a 
detrimental effect on host with increased bacterial loads, enhanced lung pathology, and mortality. 
Moreover, PKCδ is critical for the accumulation of lipid bodies in macrophages and lungs during 
Mtb infection. Mechanistically, PKCδ is important for optimal killing effector functions, 
independent of phagosome maturation and autophagy in macrophages. 
RESULTS 
Increased expression of PKCδ during active tuberculosis disease  
Recently, we identified a transcriptomic signature that has the potential to distinguish latent 
infection from the development of active disease [116]. Given the pivotal role of PKCδ in signal 
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transduction, we asked whether expression of this kinase changed during the transition from Mtb 
infection to TB disease. We analyzed gene expression data in whole blood from a nested control 
study correlating risk of TB from 800 days prior to diagnosis. This included 46 adolescents with 
latent Mtb infection who progressed to active disease (progressors) and 107 adolescents with Mtb 
infection who remained healthy [116]. PKCδ was significantly upregulated in progressors when 
compared to latently infected healthy controls (Figure 1a). Although two PKC isoforms ( and ) 
exhibited down-regulation during progression to active TB disease, the expression levels of other 
PKC isoforms (α, β, , ,  and ) remained constant (Supplementary Figure S1). This highlighted 
PKCδ as a possible marker of active TB disease which we sought to validate using qRT-PCR. 
PKCδ mRNA expression was significantly higher in whole blood from eight participants with 
pulmonary TB disease when compared to sixteen healthy controls with or without latent Mtb 
infection (QuantiFERON +/-) (Figure 1b). This finding was confirmed in whole blood of a larger 
independent Strategic Health Innovation Partnerships (SHIP) cohort of 30 active tuberculosis 
participants and 30 healthy individuals with latent Mtb infection, too (Figure 1c). Additionally, 
human monocyte-derived macrophages (MDMs) also upregulated PKCδ expression, following 
Mtb infection (Figure 1d). Collectively, these data indicate that PKCδ expression increases during 
active TB disease and in vitro Mtb infection of macrophages. 
We then investigated whether anti-tuberculosis therapy would decrease PKCδ expression. 
We analyzed a publicly available dataset from an independent study [217], which reported whole 
blood expression profiles of 27 first-time TB patients before and after treatment. PKCδ was the 
most abundantly expressed isoform compared to other PKC isoforms. The expression decreased 
starting from week 1 to 26 weeks of successful treatment with antituberculosis therapy (Figure 
1e). Of note, all other PKC isoforms remained unchanged before and after tuberculosis therapy 
except PKC, which was marginally increased only at completion of treatment (Figure 1e). This 
decline in PKCδ expression after treatment suggests that it can be an important component or 
mediator of the host immune response during active TB disease. 
PKCδ is highly expressed in necrotic and cavitory regions of granulomas in patients with 
Multi-Drug Resistant tuberculosis 
We recently characterized proteomic signatures in various regions of granulomas from 
treatment-refractory TB patients who had undergone pneumonectomy due to severe lung damage 
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[187]. Using the proteomics data, we determined the protein expression levels of various PKC 
isoforms. Our analysis revealed that only PKCδ was associated with the necrotic regions of both 
caseous and cavitory granulomas (Figure 1f) whilst other PKC isoforms were largely absent in 
the lung tissue samples (data not shown). This suggests an association of PKCδ within the regions 
of Mtb-specific host immune responses at the site of disease. The abundance of PKCδ protein at 
the sites of exaggerated disease strengthens our transcriptomic findings in whole blood, 
highlighting that PKCδ can be an important host factor that is induced during the transition of 
cellular to necrotic granulomas in humans.  
PKCδ is critical for host survival against Mtb infection in mice 
To further investigate how PKCδ influences host mortality during Mtb-infection, we 
compared PKCδ-/- mice [201, 202] with wild-type controls in a murine model of experimental 
tuberculosis. Deletion of PKCδ rendered mice highly susceptible to various doses of intranasal 
Mtb infection (Figure 2a, d, and g). Earlier and increased mortality was associated with rapid 
weight loss (Figure 2b, e, and h) and increased bacterial titers in the lungs and spleen determined 
at the time of euthanasia (Figure 2c, f and i). Thus, PKCδ deficiency in mice results in increased 
bacterial burdens and mortality during Mtb infection. 
Exacerbated histopathology and reduced accumulation of lipid bodies in the lungs of PKCδ-
/- mice during Mtb infection 
Since PKCδ mice succumbed to Mtb infection as early as 4 weeks in mortality studies 
(Figure 2), we performed an in-depth analysis of disease parameters at 4 and 8 weeks, using a 
dose of 1000 CFU. At 4 and 8 weeks post-infection, PKCδ-/- mice displayed higher lung and spleen 
burdens (Figure 3a), corroborating the mortality findings. Susceptibility to infection in PKCδ-/- 
mice was further accompanied by a significant increase in lung inflammation as revealed by lung 
weight index (Figure 3b), higher pulmonary cell recruitment (Figure 3c) and larger lesion area in 
H&E-stained lung sections at 4 and 8 weeks after infection (Figure 3d). Furthermore, 
immunohistochemistry revealed that iNOS production was significantly increased in the lungs of 
PKCδ-/- mice, concomitant with increased pulmonary tissue pathology indicating that PKCδ 
contributes to the control of lung pathology (Figure 3e). Given the importance of PKCδ in the 
accumulation of cholesterol in human monocyte-derived macrophages [218] we also investigated 
neutral lipid accumulation in the lungs of PKCδ-/- mice.  We found at 4 and 8 weeks after infection, 
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PKCδ-/- mice displayed significantly reduced accumulation of lipids in lungs when compared to 
control animals revealed by Oil Red O staining of tissue sections. (Figure 3f). We next assessed 
whether inhibiting PKCδ in wild-type mice using a specific peptide inhibitor TatVδ1.1 [219] 
would recapitulate exaggerated lung pathology of PKCδ-/- mice following Mtb infection. Indeed, 
mice treated with TatVδ1.1 had significantly higher lung weight index, more inflamed lung 
sections and lesion size when compared to control animals (Supplementary Figure S2a-c). 
Together, these results demonstrate that absence of PKCδ in Mtb infection resulted in exacerbated 
pathology and reduced accumulation of lipids in the lungs. 
Increased pro-inflammatory cytokine responses in the lungs of PKCδ-/- mice following Mtb 
infection 
Following excessive lung pathology as a consequence of increased bacterial loads in PKCδ-
/- mice (Figure 3d), we measured the proinflammatory cytokines profile in the lungs. Compared 
with wild-type, PKCδ-/- mice showed marked increases in pro-inflammatory cytokines including 
IFN-, TNF, IL-1β, IFN-β and IL-6 with minor effect on IL-10 at week 4 (Figure 4a) and week 8 
(Figure 4b) after infection. The extent of proinflammatory cytokines response in the lungs of wild-
type mice is, in fact, Mtb infection dose-dependent phenomenon (Supplementary Figure S5f). 
Furthermore, flow cytometric analysis of various pulmonary immune cell populations in PKCδ-/- 
mice after 4 and 8 weeks of infection, demonstrated that frequencies and total cell numbers of 
alveolar macrophages, (Figure 4c, f, i and l) and dendritic cells (Figure 4d, g, j, and m), were 
significantly decreased with concomitant increase in activated macrophages (Figure 4g) when 
compared to control mice. Of note, we observed no major differences in the frequencies and cell 
numbers of lymphocytes (CD4+ and CD8+ T and B cells) (Figure 4e, h, k, and n) or neutrophils 
(Figure 4c, f, i and l) infiltrating the lung during infection. Gating strategy to define alveolar 
macrophages and dendritic cells in the lungs are shown (Supplementary Figure S2d, e). 
Additionally, we show that percentage of T-cells were decreased whilst dendritic cells were 
increased in thoracic lymph nodes at 4 weeks (Supplementary Figure S3a-d) however no 
differences were observed at 8 weeks post infection (Supplementary Figure S3e-h). Higher 
mycobacterial burdens during TB infection along with increased proinflammatory cytokines might 
be responsible for the increased mortality observed in PKCδ-/- mice during Mtb infection. 
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Decreased fatty acids in serum of PKCδ-/- mice following Mtb infection 
Decreased lipid accumulation in lungs of PKCδ-/- mice during Mtb infection prompted us 
to perform a total metabolome analysis of the serum in these animals. Principal Component 
Analysis (PCA) shows a clear differentiation between Mtb-infected (1000 CFU) wild-type and 
PKCδ-/- mice at 4 weeks (62% variance) and 8 weeks (64% variance) post infection, respectively 
(Figure 5a and b). Metabolite profiles of these two groups thus varied significantly to allow a 
natural grouping of the individual samples. Considering these results, Mtb-infected PKCδ-/- mice 
showed significantly decreased levels of all serum fatty acids when compared to wild-type mice, 
except for mead acid, an elevation of which is a well-known marker for fatty acid deficiencies 
[220]. Here, we selectively report that host protective (arachidonic acid, α-linoleic acid, and 
palmitic acid) [221] and host detrimental (behenic acid, cervonic acid or DHA and timnodonic 
acid or EPA) [221] fatty acids were significantly lower in the PKCδ-/- mice during Mtb infection 
(Figure 5c and d). To assess whether the observed effect was indeed PKCδ specific and not as a 
consequence of morbidity and pathology at this dose resulted in reduced food and water intake, 
we performed metabolomics at a low dose (70 CFU) and found similar results (Supplementary 
Figure S5a-d) to 1000 CFU. Moreover, we also confirmed that the changes in lipid profiles were 
not a function of bacterial loads in the lungs of wild-type mice (Supplementary Figure S5e). 
Thus, the absence of PKCδ led to a modest decrease in serum fatty acids of Mtb-infected mice. 
Macrophages deficient in PKCδ exhibit reduced mycobacterial killing capacity and reduced 
accumulation of lipid bodies 
Using our publically available dataset from CAGE sequencing of macrophages infected 
with a hypervirulent Mtb strain (HN878) [122], we report that PKCδ in the murine BMDMs was 
also upregulated, whereas other PKC isoforms (except Prkcb) remained largely unaffected (Figure 
6a), PKCδ expression was also validated by qRT-PCR in murine macrophages (Supplementary 
Figure S4a). Given the entire study was performed with an H37Rv strain of Mtb, we also measured 
the expression of PKCδ in H37Rv-infected macrophages (Figure 6b), which had slightly different 
kinetics at 24 hours post infection when compared to HN878-infected macrophages (Figure 6a 
and Supplementary Figure S4a). This discrepancy in expression kinetics at the indicated time 
point was most likely due to the different strains of Mtb. We next investigated the intracellular 
growth of Mtb in primary macrophages deficient for PKCδ. Mycobacterial growth was 
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significantly increased in PKCδ-/- macrophages at 3 and 6 days after infection (Figure 6c) as well 
as in wild-type macrophages transfected with anti-PKCδ siRNA at 48 hours post-infection 
(Supplementary Figure S4b). In PKCδ-/- mice, we found a reduced accumulation of the lipid 
bodies in the Mtb-infected lungs. Likewise, PKCδ-/- macrophages displayed fewer lipid bodies 
following Mtb infection in a time-dependent manner as shown by the Oil Red O staining (red) in 
fluorescent microscopy concomitant with significantly higher bacterial numbers shown as green 
fluorescent protein-expressing Mtb (Rv-GFP) (Figure 6d and e). Unlike in the in vivo model, we 
found no differences in cytokine production by PKCδ-/- BMDMs except for a significant decrease 
in IL-6 (Figure 6f-i) suggesting other cell populations contributed in total cytokine production in 
the lungs or CFU difference between the groups is not substantial as in vivo which does not drive 
higher cytokine production. Thus, PKCδ is important for macrophage-mediated containment of 
mycobacteria and lipid accumulation. 
Killing effector functions in Mtb-infected PKCδ-/- macrophages 
The PKC isoforms including β [222] and α [223] were reported to be important for 
maturation of Mtb-containing phagosomes. In bacterial infection, we previously reported that 
PKCδ is critical for containment of Listeria monocytogenes in phagosomes of macrophages [201]. 
Surprisingly in Mtb infection, no differences in the analyzed phagosome markers including 
LAMP-1, LAMP-3, Cathepsin D and an autophagy marker LC3-II were observed between PKCδ-
/- and control macrophages (Figure 7a-b). This result suggests that PKCδ is dispensable for 
phagosome and autophagy-mediated killing of Mtb in macrophages. 
Since the intracellular killing of Mtb is enhanced by nitrogen and oxygen species [224], we 
measured the ability of macrophages to release reactive oxygen species (ROS), hydrogen peroxide 
(H2O2) and nitric oxide (NO). We report nitric oxide production was significantly decreased in 
PKCδ-/- macrophages at the protein level (Figure 7c) and confirmed at mRNA level using qRT-
PCR (Figure 7d). To assess whether this led to concomitant increase in Arginase 1 (Arg1) 
expression since both iNOS and Arg1 utilizes same substrate (L-arginine). To our surprise, the 
expression of Arg1 was also significantly decreased in a time-dependent manner when compared 
to control macrophages (Figure 7e). Further, we also found that PKCδ is upregulated with IL-4 
stimulation in Mtb-infected macrophages from our CAGE dataset (Supplementary Figure S4c). 
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In addition to NO, the release of H2O2 (Figure 7f) and reactive oxygen species (ROS) 
(Figure 7g) was also significantly decreased in the PKCδ-/- macrophages. Further, the absence of 
PKCδ in macrophages also renders them more prone to apoptosis, revealed by Annexin V and 7-
AAD staining following Mtb infection (Figure 7h). Moreover, we also evaluated the possible 
effect of antimicrobial molecules secreted into the cell supernatant by Mtb-infected macrophages 
by treating infected PKCδ-/- cells with supernatants from wild-type cells, and vice versa. 
Supernatant from infected wild-type macrophages indeed reduced bacterial growth in Mtb-infected 
PKCδ-/- macrophages (Figure 7j). This indicates that a deficiency of PKCδ decreases optimal 
oxidative and nitrosative killing effector functions in macrophages thereby favors bacterial growth. 
Oleic acid increased bacterial growth in PKCδ-/- macrophages 
Of interest, from decreased lipids in lungs (Figure 3f), macrophages (Figure 6d) and 
serum fatty acids (Figure 5c and d) of PKCδ-/- mice. We asked whether foam cell formation using 
ox-LDL (oxidized low-density lipoproteins) would control the growth of Mtb in otherwise 
susceptible PKCδ-/- macrophages. We found no differences in bacterial growth in PKCδ-/- 
macrophages cultured in presence of ox-LDLs for 3 days when compared to untreated cells 
(Figure 7i). On the other hand, ox-LDL-treated wild-type macrophages revealed a significant 
increase in bacterial growth when compared to untreated cells (Figure 7i), most likely due to foam 
cell formation and alternative activation of macrophages (M2). Furthermore, we evaluated the 
effect of an unsaturated (Oleic Acid), saturated (Palmitic Acid) fatty acids and Native-LDLs on 
PKCδ-/- macrophages. In contrast to ox-LDL, we found a significant increase in growth of Mtb in 
PKCδ-/- macrophages (Supplementary Figure S4d) with concomitant decrease in production of 
nitric oxide (Supplementary Figure S4e) in presence of oleic acid and native-LDL but not with 
palmitic acid despite a modest decrease in nitric oxide production (Supplementary Figure S4d-
e). This suggests that fatty acids have a differential effect on the role of PKC-delta in mycobacterial 
survival in vitro. Supplementation of PKCd KO macrophages with fatty acids did not reverse 
susceptibility of PKCd KO macrophages which means the role of PKCd on lipid accumulation 
might not be a major contributing factor on increased mycobacterial burdens in vitro.  
DISCUSSION 
We have demonstrated the functional role of PKCδ in host defense against Mtb infection. 
PKCδ is highly expressed in human whole blood during active tuberculosis disease progression as 
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well as within the Mtb-specific pro-inflammatory regions of necrotic and cavitory lung granulomas 
during TB disease. These regions of high pro-inflammatory signatures, are required for an early 
control of bacterial replication and could lead to necrotic damage (caseation) and consequent 
cavity formation if not appropriately regulated [225]. This was indeed evident in this study, where 
PKCδ was more abundant in the caseous and cavitory regions, colocalizing with antimicrobial 
signatures [187] and the regions of abundant lipids in granulomas [226]. Consistent with this, we 
found PKCδ as an indicator of lung inflammation in yet another whole blood transcriptome dataset 
from pulmonary infections such as sarcoidosis, tuberculosis, pneumonia, and lung cancer [227].  
Given the non-specificity to TB and substantial overlap in PKCδ expression between healthy 
participants and TB patients, the gene offers a limitation to be used as a prognostic marker for 
tuberculosis. Mass spectrometry additionally confirmed that the expression of PKCδ varies within 
the regions of lung granuloma. Importantly, anti-tuberculosis therapy decreased PKCδ expression 
in whole blood of human patients, reflecting a potential role for this protein kinase as a host factor 
regulating Mtb-driven inflammation.  
Our findings revealed that PKCδ is indeed associated with host defense against murine 
tuberculosis since PKCδ ablation enhanced mortality with rapid weight loss, high bacterial loads 
and exacerbated lung pathology in Mtb infected mice. In these mice, we found higher levels of 
lung proinflammatory cytokines during Mtb infection which was consistent with our previously 
published reports on the role of PKCδ in listeriosis [201] and cutaneous leishmaniasis [202]. 
Notably, inhibition of PKCδ using a specific peptide inhibitor-TatVδ1.1 [219] recapitulated 
aggravated lung inflammation in PKCδ-/- mice during Mtb infection; revealing a direct role of this 
kinase in regulation of Mtb-driven lung inflammation.  
Consistent with the essential role of alveolar macrophages in controlling Mtb infection in 
mice [228], we found strikingly reduced numbers of these macrophages with concomitantly higher 
lung bacterial loads which could lead to necrosis in PKCδ-/- mice. To control infection, activated 
macrophages and monocytes would be recruited, perhaps contribute in excessive nitric oxide in 
the lungs, in contrast to reduced iNOS expression in PKCδ-/- macrophages. Notably, mice deficient 
for alveolar macrophages also result in higher accumulation of intracellular lipids in the lungs 
[229]. This effect on lipid homeostasis is unlikely to recapitulate in PKCδ-/- mice since the absence 
of this kinase would result in excess lipid efflux from the macrophages, therefore, decreased lipid 
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accumulation and diminished production of lipogenic enzymes. Our findings suggest that PKCδ 
is required for maintenance of an optimal inflammatory balance during Mtb infection, which is a 
key factor in limiting immunopathology to host lung tissue. We infer from these findings deletion 
of PKCδ in mice renders them hyper-susceptible to tuberculosis, therefore it is likely that increased 
expression (blood) and abundance (granulomas) of this kinase reflect its role as a host factor to 
contain inflammation in humans. 
Host lipid bodies provide an excellent nutrient source for the survival of Mtb in host cells 
[45] thereby decreasing its own metabolism [230], which allows pathogenesis [231]  and 
persistence of the bacterium [232-234]. Consistent with the necessity of triacylglycerol for slow-
replication, a recent study demonstrated that deposition of excessive triacylglycerol in Mtb 
bacterium slowed down its growth as opposed to a Mtb strain capable of pumping out lipids [235]. 
Reports have indicated a critical role of PKCδ in the accumulation of cholesterol in human [218] 
and mouse macrophages [213]. Corroborating with these findings, we found that PKCδ is indeed 
critical for the accumulation of lipids in the lungs, macrophages and to a lesser extent in the case 
of fatty acids in sera following Mtb infection. Notably, it has been shown that in steady state 
absence of PKCδ is dispensable for the uptake of ox-LDL to induce foam cell formation in murine 
and human macrophages [236]. Further, our observations of Mtb in PKCδ-/- macrophages in 
presence of unsaturated, saturated fatty acids, oxidized and native LDL support that the type of 
lipid contributes to foam cell formation that may not necessarily contribute to the intracellular 
bacterial growth. Recently, a published report has shown that increased lipids in lungs and 
macrophages drive the polarization of macrophages (M2) involved in fibrosis [237]. In PKCδ-/- 
mice, the decreased availability of lipids and enhanced pro-inflammatory cytokines, in addition, 
reduced Arg1 expression in macrophages might have limited tissue repair processes in the lungs. 
Thus, lipid accumulation can be the consequence, rather than the cause of susceptibility to Mtb 
infection in PKCδ-/- mice. This Mtb-driven modulation of host lipids may be the means by which 
this highly evolved pathogen controls its replication rate in vivo. It is feasible that inability of 
PKCδ-/- mice to accumulate intracellular lipids hampers the ability of Mtb to undergo persistent, 
slow-replicative state during infection.  
Intracellular Mtb can be eliminated by the induction of macrophage phagosome maturation 
[238] and autophagy [83]. The PKC isoforms including β [222] and α [223] were reported to be 
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important for maturation of Mtb-containing phagosomes. In contrast to PKCβ and α, our findings 
indicate that phagosome maturation and autophagy occurs independently of PKCδ in Mtb-infected 
macrophages. An alternative explanation is given PKCδ, unlike other isoforms (α, β and ), is 
insensitive to calcium signaling [239] which is important for phagosome maturation. Another 
isoform PKC has been implicated as a key factor for ERK1/2 and TLR2 mediated secretion of 
TNF both in murine and human macrophages following Mtb infection in vitro [240]. Whilst a 
recent study has demonstrated that inhibition of PKCδ with rottlerin abrogates apoptosis in murine 
macrophages when cultured with cell-free supernatant of Mycobacterium indicus pranni (Mw) 
[241]. In contrast, we observed increased apoptosis in PKCδ-/- macrophages following Mtb 
infection. This observation strengthens accumulating evidence regarding the non-specific actions 
of rottlerin as a PKCδ inhibitor [211, 236]. 
It is well-established that within macrophages, Mtb can be successfully eliminated by 
oxidative (ROS, H2O2) and nitrosative (nitric oxide) killing functions [224]. Interestingly, IFN- 
activated macrophages synergistically increase nitric oxide production 5-fold upon PMA-mediated 
PKC activation in M. bovis (BCG) infected macrophages [242]. Indeed, this was confirmed in our 
study since the presence of PKCδ enhanced killing effector functions whereas the absence thereof 
inhibited these effector responses thereby reducing the mycobacterial killing capacity of PKCδ-/- 
macrophages. Interestingly, in addition to reduced iNOS, this study shows decreased Arg1 
expression in PKCδ-/- macrophages. We also found increased expression of PKCδ in Mtb-infected 
macrophages stimulated with IL-4. This evidence provides support for the possibility that PKCδ 
has an important role in the macrophage plasticity. We infer from these findings that PKCδ has a 
role in macrophage polarization during lung infections in vivo.  
Collectively, our data revealed that PKCδ is an indicator of inflammation in both systemic 
and local tissue compartments during active tuberculosis disease progression in humans. Global 
deletion of PKCδ worsens the disease outcome in mice which exaggerated mortality with a shift 
towards increased bacterial burdens, exacerbated pathology and excessive pro-inflammatory 
responses. To a lesser extent following Mtb infection, decreased lipids in lungs and macrophages 
of PKCδ-/- mice further eliminate the possibility for this bacterium to undergo persistence, however 
not the cause of increased burdens. Mechanistically, reduced killing effector functions in 
macrophages increased susceptibility to Mtb in the absence of PKCδ. Taken together, the onset of 
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active human Mtb disease correlates with PKCδ expression and conferring from our murine model, 
PKCδ might be a critical factor employed by the host to control exacerbation of Mtb infection. 
METHODS 
Whole blood mRNA signature of PKC 
For whole blood transcriptomics, we analyzed the publicly available RNA-Seq data set 
from the Adolescent Cohort Study [116]. We determined expression profiles of all PKC isoforms 
from 800 days prior to diagnosis of tuberculosis disease.  
A cross-sectional cohort of TB disease and healthy control participants  
A cross-sectional study of 30 healthy HIV-negative adults with latent Mtb infection and 30 
HIV-negative adults with active pulmonary TB disease, recruited from the Western Cape region 
of South Africa. The human Study protocol (HEC: 288/2008) was approved by the University of 
Cape Town, Human Ethics Committee. Participants were recruited following written informed 
consent prior to inclusion in the study. Latent Mtb infection was diagnosed by QuantiFERON TB 
Gold in-tube assay (Qiagen, IFN- levels > 0.35 IU/mL) and TB disease was diagnosed as sputum-
positive positive Xpert MTB/RIF test (Cepheid). Whole blood in PAXgene blood RNA tubes 
(PreAnalytix) was collected from each participant. 
Human PKCδ expression following treatment and lung proteomics from treatment-
refractory tuberculosis patients 
The blood gene signature from the publically available data set in the NCBI-GEO database, 
accession number GSE31348 was used to analyze PKC expression of all isoforms during 
tuberculosis treatment [217]. For human lung proteomics, we analyzed the publicly available data 
that have been deposited into the PRIDE partner repository with the dataset identifier PXD003646. 
The heat map plot was constructed by calculating z-scores of PKCδ abundance in different types 
of granulomas derived from multi-drug resistant TB patients who had undergone pneumonectomy. 
Details of the patients and surgical procedures have been described previously [187].  
Mice 
Protein Kinase C-delta (PKCδ-/-) deficient mice on the 129Sv genetic background (8-12 
weeks) were maintained under specific-pathogen-free conditions in individually ventilated cages. 
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All experiments were performed in accordance with the South African National Guidelines and 
University of Cape Town practice for laboratory animal procedures. The protocol (AEC: 012/036) 
was approved by the Animal Ethics Committee, Faculty of Health Sciences, University of Cape 
Town, Cape Town, South Africa.  
Mtb infection and determination of bacterial loads in mice 
Mtb (H37Rv) was grown to log phase in 7H9 complete media, and stocks were prepared 
for infections via an intranasal route as described previously [243]. Bacterial loads in lungs and 
spleen of Mtb-infected mice were determined at different time points post-infection. Briefly, 
organs from euthanized mice were removed aseptically, weighed and homogenized in 0.04% 
Tween 80. Ten-fold dilutions were plated onto Middlebrook 7H10 agar plates supplemented with 
10% OADC and 0.5% glycerol and incubated at 37°C for 21 days before colonies were counted. 
Histopathology, immunohistochemistry and lipid staining of the lung sections 
Formalin-fixed (10%) lung tissue from Mtb-infected mice was cut into 3-micron sections 
and stained with H&E for histopathological analysis. For iNOS staining, immunohistochemistry 
was performed using rabbit anti-mouse iNOS (Abcam) as described previously [191]. Neutral 
lipids were analyzed in lung sections of Mtb-infected mice or macrophages by Oil red O (Sigma) 
staining for 5 minutes following washing and then a rinse with 60% isopropanol [244]. Sections 
were mounted using the gelatine-based mounting medium. Image acquisition and quantification 
of lesion area, iNOS staining and area covered by lipid bodies were performed on a Nikon 90i 
microscope using NIS advanced software. 
Cytokine responses and immune cell populations in lungs using FACS 
Supernatants from lung homogenates were collected for the determination of cytokines. 
IFN-, TNF, IL-6, IL-10 (all BD Biosciences) and IL-1β (R&D Systems) and IFN-β (BioLegend) 
productions were quantified in these supernatants by ELISA. Single cell suspension of Mtb-
infected was lungs was prepared following collagenase digestion as previously described [191].  
Cells were then stained for lymphocytes (CD4+ T cells, CD8+ T cells and B cells) and myeloid 
populations (alveolar macrophages, activated macrophages, dendritic cells, and neutrophils). 
Surface phenotyping of various cell populations was performed using the following antibodies; 
CD3-FITC, CD4-PE, CD8-APC, CD19-PerCP, CD11c-APC, CD11b-PE, MHC II-FITC, Siglec-
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F-PE and Gr-1-FITC (all BD Biosciences). Cells were acquired on a FACS Calibur and the data 
was analyzed using FlowJo software (v10.1, Tree star) as described previously [191]. 
Metabolome analysis in serum of PKCδ mice using GC-MS 
Extraction of the collected serum samples from Mtb-infected PKCδ-/- and wild-type mice 
at 4 and 8 weeks post-infection was performed as previously described [245] using 50 µL of 0.45 
µg/mL 3-phenylbutyric acid (Sigma-Aldrich), as an internal standard prior to GC x GC-TOFMS 
analyses.  
Mtb infection in vitro 
Murine BMDMs and human MDMs were generated as previously described [243]. 
Macrophages were either treated with ox-LDL (100µg/ml) or native-LDL (125µg/ml) or oleic acid 
(500µM) or palmitic acid (500µM) or left untreated overnight. Cells were then infected in presence 
of treatment(s) with Mtb (H37Rv, unless otherwise indicated) with MOI of 2 for 4 hours followed 
by two washes with the pre-warmed medium. At indicated time points, cells were lysed in 0.1% 
Triton-X-100 for determination of bacterial growth or fixed using paraformaldehyde (4%) for 
visualization of bacteria and Oil Red O staining. Images were acquired using a Carl Zeiss 510 
confocal microscope and bright field images were analyzed for the area under the lipid stain as 
mentioned above. 
Quantitative RT-PCR from whole blood, MDMs, and BMDMs 
Sixteen RNA samples from QuantiFERON positive and negative and eight tuberculosis 
progressor subjects were validated for the expression of PKCδ using qRT-PCR from the 
Adolescent Cohort Study. As per manufacturer’s instructions, RNA was extracted from whole 
blood (PAXgene blood RNA kit, Qiagen). cDNA was synthesized from RNA using Superscript II 
Reverse Transcriptase (Life Technologies). Mtb-infected BMDMs or MDMs were reverse 
transcribed by Transcriptor First Strand cDNA Synthesis Kit (Roche) according to manufacturer's 
instructions. Real-time PCR was performed with LightCycler® 480 SYBR Green I Master mix 
using a LightCycler® 480 II (Roche) for relative expression of PKCδ relative to HPRT 
housekeeping gene. 
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Western Blot Analysis 
SDS-PAGE and Western Blot analysis was performed as previously described [243]. 
Briefly, macrophages (3x106) were infected with Mtb at MOI of two for 4 hours. Cells were 
washed and then lysed with ice-cold RIPA buffer containing protease inhibitors for 30 minutes at 
4°C. Total cell lysates were analyzed for protein contents using BCA assay (ThermoFisher). An 
equal amount of protein (40 μg) were then electrophoresed on 12% SDS-PAGE and transferred to 
a nitrocellulose membrane (Sigma). The membrane was probed with anti-LAMP-1, LAMP-3, 
Cathepsin D, LC3-II and GAPDH primary antibodies diluted (1:200) in blocking buffer at 4°C 
overnight. The membrane was then incubated with the HRP-conjugated secondary antibody 
(1:10,000) for 1 hour at room temperature in blocking buffer. Immunoblots were developed using 
Super Signal West Dura substrate (Pierce). 
Measurements of nitric oxide, hydrogen peroxide and reactive oxygen species in BMDMs 
Cell supernatants from infected macrophages were collected for measurement of nitric 
oxide using Griess reagent. Hydrogen peroxide (H2O2) release from macrophages was measured 
using colorimetric detection kit (Amplex Red Hydrogen Peroxide Assay, ThermoFischer). 
Reactive oxygen species was determined in macrophages using nitroblue tetrazolium (NBT, 
Sigma-Aldrich), which is reduced to a dark-blue insoluble formazan. Cells were incubated for 
phosphate buffered saline containing 0.2% NBT for 90 minutes. Formazan was dissolved in 0.04% 
HCL in isopropanol, and the absorbance was determined at 560 nm [246]. 
Statistics 
All data were analyzed using Graph Pad Prism v 6.0, a student t-test (two-tailed with 
unequal variance) unless otherwise stated. A ‘p’ value of less than 0.05 was considered significant.  
FIGURE LEGENDS 
Figure 1 Increased expression of PKCδ in human whole blood, lungs of TB patients and Mtb-
infected macrophages. (a) PKCδ mRNA expression in TB progressors, expressed as log2 fold 
change over matched controls, from Adolescent Cohort Study (ACS) group. The dotted line 
represents the mean log2 fold change, nonlinear spline function in 46 progressors and 107 healthy 
QuantiFERON positive controls. The blue shaded area represents 99% confidence intervals. (b) 
mRNA expression of PKCδ measured in an independent QuantiFERON negative or positive 
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controls, or patients with active TB disease, from ACS group in A (n = 8-16). (c) PKCδ mRNA 
expression validated by qRT-PCR in whole blood from SHIP cohort in adults with active TB 
disease before the initiation of drug treatment (n = 30) or QuantiFERON positive healthy controls 
(n = 30, LTBI, latent Mtb infection). (d) PKCδ mRNA expression in MDMs of healthy donors 
after Mtb infection in vitro (n = 2). (e) mRNA expression of PKC isoforms following the onset of 
antitubercular treatment in human TB patients (n = 27). (f) Heat map of z-score and log2-
transformed label-free quantification of PKCδ in different types of human granulomas, excised 
from patients infected with multi-drug resistant Mtb (n = 5). Data are represented as mean ± SEM, 
analyzed using unpaired, student t-test (c), One Way ANOVA (b-e), * p < 0.05, ** p < 0.01, *** 
p < 0.001, **** p < 0.0001 versus control. 
Figure 2 PKCδ-/- mice displayed enhanced mortality and mycobacterial burdens. Mice were 
infected with a range of Mtb (H37Rv) doses via intranasal challenge for mortality studies. Survival 
curve, body weight change and lung bacterial burden determined at the time of euthanasia. (a-c) 
5000 CFU after 6 weeks. (d-f) 1000 CFU after 8 weeks. (g-i) 350 CFU after 18 weeks. Mortality 
curves were analyzed by Kaplan-Meyer survival test, ** p < 0.01, *** p < 0.001 versus WT control 
mice. Data are represented as mean ± SEM of 9-10 mice/group, analyzed using unpaired, student 
t-test, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control. 
Figure 3 PKCδ-/- mice displayed increased lung pathology, nitric oxide and decreased lipid 
accumulation in the lungs. Mice were infected with Mtb (1000 CFU) via intranasal challenge. 
(a) Bacterial burden in lungs and spleens were determined at 4 and 8 weeks after infection. (b-c) 
Lung weight index, as a proxy for inflammation and a total number of cells harvested at 4 and 8 
weeks after infection. (d-f) Representative images and quantification of (d) histopathology H&E 
staining and lesions, (e) immunohistochemistry for iNOS and (f) Oil Red O staining for lipids at 
the indicated time points. Data are represented as mean ± SEM of n = 4-5 mice/group and 
representative of two independent experiments. Data is analyzed using unpaired, student t-test, * 
p < 0.05, ** p < 0.01, *** p < 0.001, versus WT control. 
Figure 4 Increased pro-inflammatory cytokine responses and the immune cell populations 
in the lungs of PKCδ-/- mice following Mtb infection. (a-b) Supernatants from lung homogenates 
were analyzed for IFN-γ, TNF, IL-1β, IL-10 and IFN-β using ELISA after 4 and 8 weeks of Mtb 
infection. Single cell suspension of lung tissue was analyzed for percentage and total cell numbers 
of immune cell populations at 4 weeks (c-h) and 8 weeks (i-n) after infection. Surface markers of 
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different cell populations as follows; B cells = CD19+CD3-, CD4 T cells = CD3+CD4+, CD8 T 
cells = CD3+CD8+, Alveolar macrophages = SiglecF+CD11c+, Activated Macrophages = 
CD11b+MHCII+CD11c-, DCs = CD11c+MHCII+CD11b- and Neutrophils = Gr1+CD11c-. Data are 
represented as mean ± SEM of n = 4-5 mice/group and representative of two independent 
experiments. Data is analyzed using unpaired, student t-test, * p < 0.05, ** p < 0.01, *** p < 0.001, 
versus WT control mice. 
Figure 5 Decreased serum fatty acids by metabolic analysis following Mtb infection. (a-b) 
PCA plots with percentage variation for each Principal Component is indicated in parenthesis on 
the respective axis at 4 weeks and 8 weeks after infection (1000 CFU). (c-d) Serum levels (µg/L) 
of selected host-protective (arachidonic acid, α-linolenic acid and palmitic acid) and detrimental 
fatty acids (behenic acid, DHA and EPA) during Mtb infection at 4 weeks and 8 weeks after 
infection. Data are represented as mean ± SD of n = 4-5 mice/group. Data is analyzed using 
univariate and multivariate statistical techniques (PCA powers > 0.5, PLS-DA VIP > 1.0, effect 
size > 0.8, and student t-test p < 0.05) versus WT control mice. 
Figure 6 Increased mycobacterial growth and decreased lipid bodies in PKCδ-deficient 
macrophages. (a) Expression of PKCδ and other isoforms in BMDMs infected with an HN878 
strain of Mtb from CAGE study. (b) PKCδ mRNA expression during H37Rv Mtb infection in 
BMDMs using qRT-PCR. (c) Increased growth of H37Rv Mtb (MOI=2) in macrophages deficient 
for PKCδ during the course of infection. (d-e) PKCδ-/- and WT BMDMs were infected with GFP-
expressing Mtb (green, H37Rv) and stained with Oil Red O (red) for visualization and 
determination of intracellular bacteria and quantification of lipid bodies (Insets is bright field 
view). (f-i) Supernatants from infected macrophages were analyzed for the production of TNF, IL-
12p40, IL-6 and IL-1β at indicated time points after infection by ELISA. Data are represented as 
mean ± SEM of quadruplicate and representative of three independent experiments, Data is 
analyzed using unpaired, student t-test, * p < 0.05, ** p < 0.01, *** p < 0.001, versus WT control 
macrophages. 
Figure 7 Decreased production of killing effector molecules in macrophages deficient for 
PKCδ but similar phagosome maturation and autophagy induction. (a-b) Western Blot and 
densitometry analysis of phagosome (LAMP-1, LAMP-3, and Cathepsin D) and autophagy (LC3-
II) markers in total macrophage cell lysates following Mtb infection. (c-d) Impaired production of 
nitric oxide in PKCδ macrophages measured by Griess reagent assay and qRT-PCR. (e) Decreased 
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mRNA expression Arginase 1 measured by qRT-PCR in PKCδ-/- macrophages. (f-g) Deficiency 
of PKCδ resulted in decreased production of hydrogen peroxide and reactive oxygen species 
(ROS). (h) Percentage of macrophages live, dead and apoptotic after 3 days of infection 
determined by Annexin V and 7-AAD staining. (i) Macrophages from wild-type and PKCδ-/- mice 
were treated overnight with or without oxidized-LDL. Cells were then infected with Mtb-
containing medium with Ox-LDL for 3 days to determine mycobacterial growth. (j) Supernatants 
from 3 days infected WT and PKCδ-/- macrophages were transferred on 4 hours infected PKCδ-/- 
(WT SN) and WT (PKCδ-/- SN) macrophages to determine bacterial growth at 3 days post 
infection. Data are represented as mean ± SEM of quadruplicate and representative of three 
independent experiments, Data is analyzed using unpaired, student t-test, * p < 0.05, *** p < 0.001, 
versus WT control macrophages. 
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CHAPTER V 
CONCLUSIONS 
 The aim of this study presented in the thesis is to better understand host-pathogen interplay 
through extensive transcriptomic analysis. Mtb as a highly successful pathogen which has been 
interacting with the human immune system more than 9000 years and evolving together with 
humans to achieve survival through manipulation of host cells. There has not been a successful 
vaccine in the market since last 90 years BCG was first started to be used clinically. Bedaquiline 
was the first FDA approved the anti-TB drug for 40 years in 2012. The emergence of HIV-TB co-
infection, multi drug resistant and extensively drug resistant cases alarmingly shows that novel 
approaches need to be developed to tackle TB. Therefore, it is imperative to explore macrophage 
responses and find novel regulations or molecular switches that can be targeted. Thorough 
comprehension of the responses of three different macrophage polarization states to Mtb can be 
crucial first step since macrophages, their transcriptional landscape and changes in their 
transcriptional landscape in response to environmental stimuli is the main feature in TB 
pathogenesis. We identified two targets based on aforementioned approach; a transcription factor 
Batf2 from classically activated macrophage responses to Mtb infection and a protein kinase PKCδ 
from alternatively activated macrophage responses to Mtb. The initial rash hypothesis was that a 
gene that is upregulated in M1 macrophages should be host protective and a gene that is 
upregulated in M2 macrophages should be host detrimental. Even though the rash hypothesis was 
valid for Batf2 in vitro analysis, Batf2 deficient mice were more protected than wild type controls. 
In terms of PKCδ, the deletion of the gene resulted in susceptible phenotype both in macrophages 
and in mice. These two genes are quite valuable examples of how the responses differ in cellular 
and systemic level. Increased expression levels of these genes in the whole blood transcriptome of 
active TB patients and an abundant presence of PKCδ in caseous regions of human TB granulomas 
suggest their potential role in human tuberculosis. 
 CAGE sequencing data of Mtb infected murine macrophages has provided us invaluable 
information about many potential protein-coding genes and noncoding RNAs, including 
microRNAs, long noncoding RNAs and enhancer RNAs to follow up; some of the genes have 
been discussed in this thesis. The author will continue to work on these candidate genes or 
transcripts to shed light on how we can help people who still suffer from this debilitating disease. 
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